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Yanique Serge Gillana Thomas 
 
HPV REPLICATION REGULATION BY ACETYLATION OF A CONSERVED 
LYSINE IN THE E2 PROTEIN 
 
Papillomaviruses (PVs) are non-enveloped DNA viruses that are the primary 
etiological agents of cervical and oropharyngeal cancers. Vaccines for 
H(human)PV have proven to be effective prophylactic treatments; however, there 
is no treatment available for those currently infected. To develop new therapies, 
we require a clear understanding of viral pathogenesis and regulation.  
 
The Papillomavirus E2 protein is a sequence specific DNA binding protein that 
recruits cellular factors to its genome in infected epithelial cells.  E2 also binds to 
and loads the viral E1 DNA helicase at the origin of replication. Post-translational 
modifications of PV E2 have been identified as potential regulators of E2 
functions. We recently reported lysine (K) 111 as a target of p300 acetylation in 
B(bovine)PV that is involved in the regulation of viral transcription. K111 is 
conserved in most papillomaviruses, so we pursued a mutational approach to 
query the functional significance of lysine in HPV E2. Amino acid substitutions 
that prevent acetylation, including arginine, were unable to stimulate transcription 
and E1 mediated DNA replication. The arginine K111 mutant retained E2 
transcriptional repression, nuclear localization, DNA and chromatin binding, and 
association with E2 binding partners involved in PV transcription and replication.  
	 v 
When directly investigating origin unwinding, the replication defective E2 K111R 
mutant recruited E1 to the viral replication origin, but surprisingly, unwinding of 
the duplex DNA did not occur.  In contrast, the glutamine K111 mutant increased 
origin melting and stimulated replication compared to wild type E2. We have 
identified Topoisomerase I as a key host factor involved in viral replication whose 
recruitment is dependent on K111 acetylation, and propose a new model for viral 
origin dynamics during replication initiation. This work reveals a novel activity of 
E2 necessary for denaturing the viral origin that likely depends on acetylation of 
highly conserved lysine 111. 
 
Elliot J. Androphy, MD (Chair) 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Papillomaviruses 
Papillomaviruses (PVs) are a family of non-enveloped DNA viruses, that are the 
major etiological agents of cervical and oropharyngeal cancers. The circular, 
double stranded DNA genome is approximately 8 kb, and is comprised of a long 
control region (LCR) (Hou, Wu, Zhou, Thomas, & Chiang) and eight open 
reading frames (Hebner & Laimins, 2006; Kadaja, Silla, Ustav, & Ustav, 2009; 
Mohr et al., 1990a; Soeda, Ferran, Baker, & McBride, 2006). This viral family is 
diverse and infects a wide range of species (Campo, 2002), currently over 30 
genotypes of PVs and over 200 human papillomaviruses (HPVs) have been 
identified. PVs are mostly host specific as well as tissue-tropic, and all HPVs 
demonstrate an affinity for basal epithelial cells (Burd, 2003).  These viruses are 
widespread and cause a wide range of diseases that vary based on the genotype 
and species in question (Table 1.1).   
 
1.2 Human Papillomaviruses and Disease 
There are over 200 HPVs that have been described and they manifest in a 
variety of ways; they can be asymptomatic, or they can result in benign lesions 
(papillomas) or progress to malignancy (de Villiers, Fauquet, Broker, Bernard, & 
zur Hausen, 2004). In the United States, HPV is the most common sexually 
transmitted infection and nearly all sexually active adults contract it at least once. 
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Although 90% of infections are asymptomatic and resolve easily (Ho, Bierman, 
Beardsley, Chang, & Burk, 1998), HPV 16 and 18 alone are responsible for 70% 
of all cervical cancers, which are almost entirely caused by HPV infection (Bosch 
et al., 1995; Clifford, Smith, Plummer, Munoz, & Franceschi, 2003). Interestingly, 
60-90% of other cancers have also been linked to HPV.  
 
PVs are categorized into high-risk and low-risk according to disease outcome. 
High risk HPVs including 16, 18, and 31, can lead to the development of 
intraepithelial neoplasia. HPV16 and 18 are the most prevalent and are 
responsible for over 70% of all cervical cancers (Munoz et al., 2004). Low-risk 
HPVs are the major causative factors of benign lesions such as laryngeal 
papillomas and genital warts.  
 
A large number of HPVs can be classified as mucosal since they infect the 
mucosal epithelium, particularly the mucosal epithelial lining of the anogenital 
and oropharyngeal tracts. PVs are classified into genera based sequence 
variations in the L1 gene. Most of the high risk HPVs are mucosal and belong to 
the alpha genus. Cutaneous HPVs belong mainly to the beta and gamma 
genera. Beta HPVs are reported to be co-carcinogens with ultra violet radiation 
(UVR) to cause various skin cancers (Accardi & Gheit, 2014). Patients who suffer 
from epidermodysplasia verruciformis (EV) and those who are immune 
compromised experience frequent occurrences of squamous cell carcinoma 
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(SCC) when exposed to certain beta HPVs (Patel, Morrison, Rady, & Tyring, 
2010).  
 
HPV is a highly prevalent infection in both developed and un-developed 
countries, but there is currently no treatment for HPV infections. In 2006 the first 
HPV vaccine was licensed, and there are currently three vaccines available 
which cover up to nine HPV types ("Human papillomavirus vaccines: WHO 
position paper, October 2014," 2014). All of the current vaccines cover HPV 
types 16 and 18, which are responsible for over 70% of all cervical cancer cases. 
The vaccines are formulated from the major capsid protein L1, and have so far 
demonstrated a 100% success rate. The multi-dose prophylactic treatment is 
recommended for use in children prior to sexual activity and potential exposure to 
the virus. Due to its high cost; however, global accessibility has been a slow 
process and many parts of the world still have no vaccine program available.  
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Table 1.1 
HPV Strain Genus Oncogenic Risk Disease Outcome 
HPV1 (cutaneous) Beta Low Plantar warts 
HPV5 (cutaneous) Beta Low Epidermodysplasia 
verruciformis 
HPV11 (mucosal) Alpha Low Benign lesions 
Respiratory 
papillomatosis 
HPV16 (mucosal) Alpha High Cervical carcinoma 
Cervical 
adenocarcinoma 
Oropharyngeal cancer 
HPV18 (mucosal) Alpha High Cervical carcinoma 
Head and neck 
cancers 
HPV31 (mucosal) Alpha High Cervical carcinoma 
Anal dysplasia 
 
Table 1.1 HPV can be classified and described by their disease 
outcomes. Different HPVs depending classification can cause a diverse 
array of disease states in human hosts.  
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1.3 Genome Structure and Viral Protein Functions 
 
The circular, double stranded DNA genome is approximately 8 kb, and is 
comprised of a long control region (LCR) (Hou et al.), an upstream regulatory 
region (URR), and eight open reading frames (ORF) (Hebner & Laimins, 2006; 
Kadaja et al., 2009; Mohr et al., 1990b; Soeda et al., 2006). The eight ORFs 
code for six early genes and two late genes and multiple splice variants. The 
LCR (Figure 1.1) contains the p97 early promoter, silencer and enhancer 
sequences, the origin of replication, and binding sites for viral and host factors 
involved in the regulation of transcription and replication (Desaintes & Demeret, 
1996). Though transient activity can be seen in cells of various human origins, 
p97 is only stably active in human keratinocytes (HFKs) (Cripe et al., 1990) and 
the late promoter is only active in differentiating keratinocytes (del Mar Pena & 
Laimins, 2001). Transcriptional regulation of viral genes is dependent on a 
collaboration of viral proteins and host factors such as activator protein 1 (AP1), 
transcription factor II domain (TFIID), and bromodomain containing 4 (BRD4) 
(Chan, Chong, Bernard, & Klock, 1990; Chong, Apt, Gloss, Isa, & Bernard, 1991; 
McPhillips, Oliveira, Spindler, Mitra, & McBride, 2006). The viral genome 
contains binding sites for some of these factors within the LCR.  
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The proteins expressed by the virus are conserved in both structure and function 
across the various PVs (Conway & Meyers, 2009). These multifunctional proteins 
and splice variants regulate viral mechanisms and manipulate infected cells 
directly and through interactions with host proteins (D'Abramo & Archambault, 
2011). The ORFs (Figure 1.2) can be divided into those that code for Early or 
Late viral proteins. The early proteins E1, E2, E4, E5, E6, and E7 are expressed 
throughout the life of the virus and are responsible for transcription, replication, 
immune evasion, and oncogenesis (Graham, 2010). The Late proteins L1 and L2 
are involved in the production of infectious particles and form the viral capsid. 
Splice variants are also expressed in certain HPVs including a transcriptional 
repressor E8^E2, pro- genome amplification E1^E4, and E6* (Lace, Anson, 
Thomas, Turek, & Haugen, 2008; Wilson, Fehrmann, & Laimins, 2005).  
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Figure 1.1 
 
 
 
 
 
 
 
Figure 1.1 Conserved LCR structure of HPV. The LCR of HPV16 highlighting 
the early promoter p97, replication origin, E2 binding sites, and enhancer and 
silencer regions. The diagram also features the location of binding sequences for 
various host factors involved in HPV regulation. This figure was modified from 
(Tan, Baker, Stunkel, & Bernard, 2003). 
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Figure 1.2 
 
 
 
Figure 1.2 HPV31 genome structure and function. This diagram 
shows the HPV31 whole genome containing the 8 ORFs and the two 
major (early and late) promoters. 
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1.3.1 E1 
 
The PV E1 protein is an essential viral replication factor (Lusky & Botchan, 1985; 
Ustav & Stenlund, 1991; Ustav, Ustav, Szymanski, & Stenlund, 1991). E1 is the 
viral helicase and initiates replication by binding to specific sequences on the 
viral genome with the assistance of the E2 protein (Frattini & Laimins, 1994). 
There is sequence and functional homology between PV E1 and SV (simian 
virus) 40 Large T Antigen which allowed for many of the predictions concerning 
E1 in foundational studies (Mansky, Batiza, & Lambert, 1997).  The c-terminus of 
E1 contains the helicase and oligomerization domains, as well as the E2 and 
DNA polymerase α interacting regions (Chen & Stenlund, 1998; Hughes & 
Romanos, 1993; Masterson, Stanley, Lewis, & Romanos, 1998) (Figure 1.3). The 
DNA binding domain (DBD) is located upstream and the localization regulatory 
region (LRR) is in the N-terminal region (Abbate, Berger, & Botchan, 2004; Amin 
et al., 2000; Sun, Han, & McCance, 1998). The LRR contains a nuclear export 
signal (NES) and a nuclear localization signal (NLS), which are regulated by 
phosphorylation.  
 
During viral replication initiation, E1 functions not only as a helicase, but is also 
reported to recruit host factors essential to viral replication including replication 
factors and chromatin remodeling complexes. E1 is reported to interact with 
replication protein A (RPA), and recruit it to sites of replication in order to stabilize 
single stranded (ss) DNA resulting from E1 helicase activity (Loo & Melendy, 
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2004).The N terminus of E1 is reported to interact with histone 1 (H1) and 
displace it from DNA, facilitating the removal histones and the melting of viral 
chromatin during replication (Swindle & Engler, 1998). H1 binds to DNA between 
nucleosomes and serves as a linker that enhances the condensing of chromatin 
(Thoma, Koller, & Klug, 1979). E1 displacement of H1 may be an essential step 
to ensure the binding of E1-E2 at the origin. E1 has also been reported to bind 
the switching deficient/sucrose non-fermentable (SWI/SNF) complex (D. Lee, 
Sohn, Kalpana, & Choe, 1999). SWI/SNF functions complex that disrupts 
chromatin to allow factors to access DNA (Travers, 1992). Other host factors E1 
is reported to functionally interact with include topoisomerase 1 (Topo1), DNA 
polymerase α primase (pol α-primase) complex, and the polymerase δ (pol δ) 
(King et al., 2010; Kuo, Liu, Broker, & Chow, 1994; P. Park et al., 1994).  
 
The E1 protein assembles as a double hexamer at the replication origin and 
unwinds viral DNA. The helicase function of E1 is driven by adenosine 
triphosphate (ATP) hydrolysis (Enemark & Joshua-Tor, 2006). The structure of 
the E1 helicase is conserved in SV40 LT helicase complexes, where each 
subunit of the helicase possesses a β-hairpin structure that is oriented to the 
center of the structure and DNA (Figure 1.3) (Enemark, Chen, Vaughn, Stenlund, 
& Joshua-Tor, 2000; Enemark & Joshua-Tor, 2006; Hickman & Dyda, 2005). The 
β-hairpins pull DNA apart while the hexamers translocate bi-directionally using 
ATP hydrolysis for energy, resulting in unwound ssDNA.  
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Figure 1.3 
 
Figure 1.3 Structure of PV E1 helicase protein. A shows the structure of the 
E1 protein, identifying the functional regions for E1 localization, helicase activity, 
and interaction with host factors essential to its function in DNA unwinding. B 
illustrates a forward view of one E1 hexamer. Each monomer is indicated by a 
different color and the center of this structure is where DNA is pulled apart by β-
hairpin processes. This figure is adapted from (Sabol, Matovina, Si-Mohamed, & 
Grce, 2012) and https://www.intechopen.com/books/the-mechanisms-of-dna-
replication/replicative-helicases-as-the-central-organizing-motor-proteins-in-the-
molecular-machines-of-the-elon  
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1.3.2 E2 
 
The PV E2 protein is the major transcriptional regulator of viral gene expression 
and a viral replication initiation protein (Androphy, Lowy, & Schiller, 1987; 
Melendy, Sedman, & Stenlund, 1995; Sedman & Stenlund, 1995; Stenlund, 
2003). The structure of E2 consists of a N-terminal trans-activation domain (TAD) 
and a C-terminal DNA binding domain, held together by an unstructured linker 
region (Figure 1.4). E2 regulates transcription by recruiting factors to the viral 
genome that result in either the activation of transcription, or repression of 
transcription (McBride, 2013), through steric hindrance or by blocking the binding 
of host transcription factors such as Sp1, TFIIB, and TBP (Hou et al., 2000; 
Stubenrauch, Leigh, & Pfister, 1996; Stubenrauch & Pfister, 1994; Yao, Breiding, 
& Androphy, 1998). Transcriptional activation involves the recruitment of certain 
host factors that are involved in chromatin processing such as chromatin adaptor 
Brd4, AMF1/GPS2, Tip60 HAT complex subunit EP400, Brm, and the 
demethylase JARDIC/SMCX (Breiding et al., 1997; Kumar, Naidu, Wang, 
Imbalzano, & Androphy, 2007; A. Y. Lee & Chiang, 2009; Peng, Breiding, 
Sverdrup, Richard, & Androphy, 2000; J. A. Smith et al., 2010; S. Y. Wu et al., 
2006). Similar to AMF1/GPS2, ubiquitin-binding adaptor Tax1BP1 has been 
shown to stabilize E2 protein levels in certain PVs (Verstrepen, Verhelst, 
Carpentier, & Beyaert, 2011). A proposed mechanism for the repression of 
transcription by E2 due to steric hindrance is based on the location of E2BS 
adjacent the TATA box, effectively blocking the binding of the TATA-binding 
protein (TBP) (Steger & Corbach, 1997).  
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Transcriptional repression of E6 and E7 by E2 is important for the stable 
maintenance of the virus, and loss of this function and subsequent increases in 
the levels of E6 and E7 may lead to the progression of malignancy with high-risk 
PVs. Studies have demonstrated that the levels of the E2 protein expressed in 
cells directly determine the levels of transcription from the viral promoter. Similar 
to E1, E2 interactions include various members of the DDR pathways that are 
proposed to be essential for replication during vegetative amplification (Hong & 
Laimins, 2013). Topoisomerase II binding protein (TopBP1) and Breast Cancer 1 
(BRCA1) were both found to interact with E2 and directly influence 
transcription/replication (Boner & Morgan, 2002; Boner et al., 2002; Kim, Lee, 
Gwan Hwang, Hwang, & Choe, 2003). 
 
E2 shows differential affinity for the E2BS and it is proposed that at low levels, E2 
binds to the high affinity sites that favor transcription, and at higher levels of E2 
transcriptional repression and replication are favored due to binding at the low 
affinity sequences. Past in-vitro studies have shown that E1 can initiate 
replication in the absence of E2 (Bonne-Andrea, Tillier, McShan, Wilson, & 
Clertant, 1997; Grossel, Sverdrup, Breiding, & Androphy, 1996; Sedman & 
Stenlund, 1995); however, E2 is essential for viral replication in-vivo due to the 
low sequence specificity of E1 (Ustav & Stenlund, 1991). E2 utilizes its high 
sequence specificity to recruit E1 to the origin in order to initiate viral replication.  
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As stated previously, E1 in-vivo is not efficient in origin binding due to poor 
sequence specificity. The recruitment of E1 to the origin by E2 is therefore 
essential to replication initiation (Stenlund, 2003). A BPV E2 mutant; E39A (also 
E39G), prevents the E2E1 interaction and maintains transcriptional function but 
inhibits replication (Sakai, Yasugi, Benson, Dowhanick, & Howley, 1996). 
Another function of E2 is the equal partitioning of viral episomes during mitosis. 
E2 is loaded onto mitotic chromosomes with the assistance of host factor ChlR1, 
where the C-terminus of E2 adheres DNA and to the mitotic spindle (Parish, 
Bean, Park, & Androphy, 2006; Parish, Rosa, et al., 2006; Skiadopoulos & 
McBride, 1998; Van Tine et al., 2004). This allows for maintenance of a constant 
copy number and even division of viral episomes between daughter cells, which 
is important in a persistent infection.  
 
One marker of HPV in cervical cancer is the integration of viral episomes into 
host chromatin and the subsequent loss of the E2 gene (Cooper, Herrington, 
Stickland, Evans, & McGee, 1991; Pett et al., 2006; Romanczuk, Thierry, & 
Howley, 1990). E2 repression of the p97 promoter regulates the expression of 
oncoproteins E6 and E7, therefore a loss of E2 results in the de-repression of 
those genes and the eventual immortalization of the infected cells (Jeon, Allen-
Hoffmann, & Lambert, 1995; Jeon & Lambert, 1995; Romanczuk & Howley, 
1992). This principle was used to develop the HeLa repression assay used in this 
study (Demeret, Desaintes, Yaniv, & Thierry, 1997). HPV infected cells with no 
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E2 expression demonstrate a proliferative advantage that is linked to E6 and E7, 
but E2 has also been reported to induce apoptosis in a transcription independent 
manner (Demeret, Garcia-Carranca, & Thierry, 2003).  
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Figure 1.4 
 
 
 
Figure 1.4 Structure of PV E2. E2 has two distinct functional regions, the N-
terminal transactivation domain and the C-terminal DNA binding and 
oligomerization domain. This figure illustrates the monomeric DBD. A flexible and 
unstructured linker region connects the functional domains of the protein. A 
portion of this figure was adapted from (M. Muller & Demeret, 2012).   
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1.4 Papillomavirus Replicative Program 
 
The viral replicative program can be separated into three defined stages; 
establishment, maintenance, and vegetative amplification. The initiation of a PV 
infection results in the establishment and maintenance of a low copy-number of 
double stranded viral episomes within infected basal keratinocytes. The PV 
replicative program is closely linked to the life cycle of the keratinocyte host cells 
and is moderated by a combination of viral and host cell factors. During 
establishment, there is an initial amplification of replication to establish a low 
copy number of viral genomes in basal cells. The maintenance stage is where 
the low copy numbers (1-10) of viral episomes are maintained in basal 
keratinocytes. Maintenance is followed by the vegetative amplification stage in 
differentiating cells of the upper epithelial strata, where the viral copy number is 
increased, late genes are expressed, and viral genomes are packaged into new 
infectious particles (Hebner & Laimins, 2006). There is a distinct correlation 
between the differentiation of keratinocytes and the switch from the maintenance 
to the amplification stage; however, the details of how the virus senses and 
progresses through these stages and how replication is regulated remain 
unknown.  
 
PVs enter the epithelium through micro-abrasions and infect basal keratinocytes 
(Schmitt et al., 1996). To facilitate viral entry, viral particles bind to the primary 
receptor hepran sulfate proteoglycans (HSPGs) on the surface of the basement 
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membrane that causes a conformational change in the L2 capsid protein 
(Giroglou, Florin, Schafer, Streeck, & Sapp, 2001; Joyce et al., 1999; Shafti-
Keramat et al., 2003). Studies have also indicated the involvement of secondary 
receptors such as α6 integrin (Evander et al., 1997; McMillan, Payne, Frazer, & 
Evander, 1999; Yoon, Kim, Park, & Cheong, 2001), CD16 (Da Silva et al., 2001) 
and laminin-332 (Cerqueira et al., 2013) in membrane attachment. After 
attachment, viral entry occurs either through caveolar or clathrin mediated 
endocytosis depending on the PV type (Hindmarsh & Laimins, 2007; J. L. Smith, 
Campos, & Ozbun, 2007). The L1 protein dissociates and L2 transports the viral 
DNA to the nucleus where it complexes with promyelocytic leukemia protein 
(PML) bodies (Day, Roden, Lowy, & Schiller, 1998).  
 
Directly following internalization of the virus and the initial amplified replication to 
establish copy number, viral replication occurs once per cell cycle (Hoffmann, 
Hirt, Bechtold, Beard, & Raj, 2006). As the infected basal cells divide, the E2 
protein assists in tethering the viral episomes to chromatin, allowing the equal 
partitioning of genomes, and maintenance of the established copy number in the 
resulting daughter cells (Skiadopoulos & McBride, 1998). One of the infected 
daughter cells then enters into the keratinocyte differentiation program. As the 
cells are actively dividing the virus adheres to the rule of replicating once per cell 
cycle; however, this changes as the cell travels up through the suprabasal 
epithelial layers and begins progressing towards terminal differentiation (Figure 
1.5) (Kajitani, Satsuka, Kawate, & Sakai, 2012). During the stage where normal 
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uninfected keratinocytes begin exiting the cell cycle, PV infected cells remain 
proliferative even though they show some signs of differentiation morphologically.  
 
Differentiation of the infected keratinocytes causes the virus to enter the 
vegetative amplification stage of its replicative program. During the amplification 
stage, the virus is able to replicate without the restraint of the cell cycle and to 
produce high copy numbers of viral genomes (Peh et al., 2002). It has been 
reported that the virus utilizes the DDR pathway to facilitate this amplified 
replication (Gillespie, Mehta, Laimins, & Moody, 2012; Moody & Laimins, 2009).   
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Figure 1.5 
 
 
Figure 1.5 The replicative cycle of Papillomaviruses. The life cycle of PVs are 
closely regulated by their host keratinocytes. This figure shows the stages of the 
viral replicative cycle, the viral genes expressed at each stage and where these 
different stages fall in reference to the keratinocyte life cycle. This representation 
is hypothetical due to the difficulty in identifying the low levels of HPV proteins in 
epithelial cells.  The late proteins E4, L1 and L2 are readily detectable. 
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The ataxia-telangiectasia mutated (ATM) branch of the DNA damage response 
pathways is activated by PVs and these factors are recruited to the viral genome. 
Both the E1 and E7 proteins have been linked to the activation of ATM. E7 is 
proposed to activate STAT5 phosphorylation which causes the activation of the 
ATM pathway (Hong & Laimins, 2013). E6 and E7 were found to independently 
activate caspases in differentiating cells (Moody, Fradet-Turcotte, Archambault, 
& Laimins, 2007). The activation of caspases was found to be essential for 
genome amplification, and a conserved caspase 3/7 cleavage site has been 
identified in E1 (Morin et al., 2011). It is proposed that this cleavage of E1 allows 
the protein to bind more efficiently and specifically to the replication and utilize 
DDR factors during amplification. At this stage, the virus shifts from the bi-
directional theta mode of replication to the bi-directional Rolling Circle mode 
(Flores & Lambert, 1997) this is controversial. At this stage, the late genes L1 
and L2 that comprise the viral capsid are expressed and viral genomes are 
packaged into infectious particles.  
  
	 22 
1.5 Papillomavirus E2 Transcriptional Regulation 
 
In the previous chapter, we established that E2 is responsible for tightly 
regulating the expression of viral genes throughout the PV life cycle (Chin, 
Hirochika, Hirochika, Broker, & Chow, 1988; Phelps & Howley, 1987; Spalholz, 
Lambert, Yee, & Howley, 1987). E2 functions in transcription by binding at E2BS, 
and depending on the context of this binding and the factors recruited, either 
activating or repressing transcription. BPV E2 is a strong transcriptional activator.  
Unlike HPV, the BPV genome has 12 E2BS within the LCR in a region called the 
minichromosome maintenance element (MME) (Piirsoo, Ustav, Mandel, 
Stenlund, & Ustav, 1996). This region is involved in the tethering of host 
chromosomes during mitosis, and the abundance of E2BS allows E2 to recruit 
host transcription factors to activate transcription. The transactivation domain of 
E2 interacts with cellular transcription factors AP1 and Sp1, bromodomain 
binding protein (Brd4), and histone acetyl transferases (HATs) CBP/p300 and 
pCAF (Ilves, Maemets, Silla, Janikson, & Ustav, 2006; D. Lee, Hwang, Kim, & 
Choe, 2002; D. Lee, Lee, Kim, Kim, & Choe, 2000; A. Muller, Ritzkowsky, & 
Steger, 2002).  
 
BPV also encodes for a number of truncated E2 proteins that do not contain a 
transactivation domain and serve as repressors (Doorbar et al., 1990; Hubbert, 
Schiller, Lowy, & Androphy, 1988). The truncated E2s such as E2C repress 
transcription by competing with full-length for the E2 binding sites, or by forming 
	 23 
heterodimers with full-length E2 (McBride, Bolen, & Howley, 1989). HPV E2 has 
been reported to be a repressor of early genes in HPV (Spalholz et al., 1987; 
Spalholz, Yang, & Howley, 1985; Thierry & Yaniv, 1987). There are only 4 E2BS 
in the HPV LCR and E2 represses transcription through steric hindrance, by 
limiting the binding of host transcription factors and through the recruitment of 
repressor complexes (Ammermann, Bruckner, Matthes, Iftner, & Stubenrauch, 
2008; Fertey et al., 2010). The early promoter of most HPVs is also regulated by 
the E2BS that coincide with the TATA box and prevent the assembly of the 
transcription initiation complex when E2 is present (Demeret et al., 1997).  
 
The E2 gene undergoes alternative splicing; splice variant E8^E2 represses both 
transcription and replication (Stubenrauch, Hummel, Iftner, & Laimins, 2000). 
Brd4 is an integral binding partner of E2 and is essential for the stability of the E2 
protein, tethering of viral genomes to host chromatin, transcription, and 
replication (McBride & Jang, 2013; McBride, McPhillips, & Oliveira, 2004; 
McPhillips et al., 2006; Sakakibara et al., 2013; Schweiger, Ottinger, You, & 
Howley, 2007; Zheng et al., 2009). E2 reacts with Brd4 through the 
transactivation domain, and splice variants as well as truncations that are unable 
to form this interaction also regulate viral processes (Abbate, Voitenleitner, & 
Botchan, 2006).  
 
During productive infection, E2 regulates the expression of the early genes and 
maintains low levels of oncoproteins E6 and E7. The E6 and E7 proteins are best 
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known for their oncogenic properties. E6 in high-risk HPV strains binds with the 
E3-ubiquitin ligase E6 associated protein (E6AP) to ubiquitylate p53 and cause 
its proteosomal degradation (Lechner & Laimins, 1994; Scheffner, Huibregtse, 
Vierstra, & Howley, 1993). High-risk HPV E7 has a similar effect on the cells by 
degrading the retinoblastoma tumor suppressor protein (RB) (Munger et al., 
1989). The E6 and E7 proteins have other functions apart from bypassing tumor 
suppressors; both E6 and E7 are required to maintain the viral genome as 
episomes, and E6 is necessary for stable genome replication (R. B. Park & 
Androphy, 2002). Our lab previously reported the inability of E6 mutants that are 
p53 degradation defective to support stable genome replication in primary 
keratinocytes. Mutation of E2 or integration of the viral genome can lead to the 
loss of E2 function, and the loss of E2-mediated repression of the E6 and E7 
genes causes the cells to progress towards malignancy (Bernard et al., 1989; 
Schwarz et al., 1985; Thierry & Howley, 1991).  
 
1.6 Papillomavirus Replication  
 
Normal mammalian replication is initiated by the recognition of an origin by the 
origin recognition complex (ORC). ORC is a complex of seven subunits and 
serves as the foundation for the assembly of pre-replication complex (pre-RC). 
ORC 2-6 are found associated with DNA throughout the cell cycle; however, 
ORC1 is only found on DNA during G1 and is released in S-phase (DePamphilis, 
2003; K. Y. Lee et al., 2012; Papior, Arteaga-Salas, Gunther, Grundhoff, & 
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Schepers, 2012). Mammalian replication is tightly regulated by a process called 
replication licensing that is modulated by the cell cycle and ensures that 
replication occurs once per cycle (Sclafani & Holzen, 2007; Truong & Wu, 2011). 
The pre-RC is composed of ORC, Cdt1 and Cdc6. Cdt1 and Cdc6 load the mini-
chromosome maintenance proteins (Mcm2-7) onto the origin, which is followed 
by the activation of the Mcms due to the loading of the pre-initiation complex 
(pre-IC). The pre-IC consists of Cdc45, the GINS complex, Mcm10, and DNA 
polymerase. Replication is then initiated by the unwinding of the origin by the 
Mcm helicase.  
 
In Eukaryotic replication the sequential loading of replication factors is closely 
linked to cell cycle progression. The formation of the pre-RC and loading of the 
pre-IC occur in late mitosis and early G1, and during S phase the Mcm complex 
is activated (Sclafani & Holzen, 2007). In the maintenance stage of the viral life 
cycle, viral replication is licensed in a similar manner and only occurs once per 
cell cycle (Hoffmann et al., 2006). During the amplification stage of the lifecycle; 
however, PVs are able to overcome the licensing restrictions and replicate 
several times per cell cycle. The mode of replication may change from what is 
known as a theta model to rolling circle model of replication (Kusumoto-Matsuo, 
Kanda, & Kukimoto, 2011). Others have proposed alternative models including 
homologous recombination. The specific factors involved PV replication licensing 
are not fully understood. 
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Figure 1.6 
 
Figure 1.6 Papillomavirus replication initiation. Viral replication begins with 
the recognition of E2BS flanking the origin by E2 and the recruitment of E1 (A) 
and the formation of a double-hexamer helicase structure of E1 following the 
removal of E2 (B).  
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Viral early proteins E1 and E2 are the only replication proteins since the viruses 
do not code for a polymerase and previous replication studies have identified the 
early proteins E1 and E2 as the only viral proteins necessary for transient 
replication of the viral genome (Sanders & Stenlund, 2001; Ustav & Stenlund, 
1991; Ustav et al., 1991). The E1 protein is the major viral replication protein, and 
it has been reported that E1 alone is sufficient to initiate viral replication in vitro; 
however, the binding of E1 to DNA is non-specific and E2 is required in-vivo 
(Ustav & Stenlund, 1991; Ustav et al., 1991).  
 
The PV replication origin contains E1 binding sites, which are flanked by high 
affinity E2 binding sites. To initiate viral replication, E2 binds to DNA in a 
sequence specific manner at the E2BS and recruits E1 to bind at the origin 
(Figure 1.6). When the first pair of E1 molecules binds to the replication origin, 
E2 is released from its binding sites through a process of ATP hydrolysis 
(Sanders & Stenlund, 1998). E2 leaving allows the ‘space’ necessary for the 
bound E1 proteins to recruit more E1 molecules and form a double-hexameric 
complex at the origin that is similar to the eukaryotic Orc-Mcm complex (Ustav & 
Stenlund, 1991). This E1 helicase complex unwinds DNA and allows host 
replication factors to be recruited to the viral genome (Sanders & Stenlund, 
1998). The loading of E2 and its regulation of E1 binding, serves as a quasi 
replication licensing system for viral replication. Without this regulation, the 
inability of E1 to bind specifically to the replication origin would cause inefficient 
and inconsistent firing of the viral origin. Though the functions of E1 and E2 
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during replication initiation have been established (Berg & Stenlund, 1997; Yang 
et al., 1993), the exact dynamics at the replication origins and the host replication 
proteins involved in this event are still being investigated.  
 
1.7 E2 Post-translational Modifications 
 
It is proposed that PV E2 undergoes certain post-translational modifications 
(PTMs) that regulate its function (McBride et al., 1989; Penrose, Garcia-Alai, de 
Prat-Gay, & McBride, 2004); however, these PTMs have been inadequately 
characterized. Phosphorylation of E2 has been studied in human and non-human 
PVs (McBride et al., 1989; Sekhar & McBride, 2012).  BPV E2 has 
phosphorylation sites in the hinge region at serines 290, 298, and 301, which 
were the first to be identified in BPV (McBride et al., 1989). These 
phosphorylations were found to regulate E2 activity; consequently, affecting copy 
number and genome maintenance in infected cells (Lehman & Botchan, 1998).  
Casein kinase II (CK2) phosphorylation at these highly conserved serine 
residues signals E2 proteosomal degradation, hereby negatively regulating viral 
replication, transcription, and copy number maintenance (McBride, Romanczuk, 
& Howley, 1991; Penrose et al., 2004). Threonine 286 in HPV16 is reported to be 
a putative phosphorylation site for Cdk2 (Johansson, Graham, Dornan, & 
Morgan, 2009). This threonine is highly conserved among alpha PVs and is 
structurally located in a similar position as the BPV serines mentioned previously. 
Another BPV phosphorylation site was described at serine 235 that enhances E2 
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activity (Lehman, King, & Botchan, 1997), demonstrating that phosphorylation 
both positively and negatively regulates E2 functions.  
 
In-vitro studies of E2 have also indicated potential sites of sumoylation. BPV and 
HPV16 E2 are both bound by ubiquitin carrier protein 9 (Ubc9) (Y. C. Wu, Roark, 
Bian, & Wilson, 2008). The site of sumoylation is K292; which is conserved in the 
majority of alpha PVs, is important for E2 transcriptional regulation. Sumoylation 
has been shown to increase the stability of E2 from HPV11, 16, and 18 (Y. C. 
Wu, Bian, Heaton, Deyrieux, & Wilson, 2009), and the coincidental increase of 
sumoylation in differentiating keratinocytes indicates that this PTM may be 
involved in the switch to amplification mode (Deyrieux, Rosas-Acosta, Ozbun, & 
Wilson, 2007). 
 
Higher levels of E2 protein are expressed in the upper layers of the epithelium 
where the virus enters the amplification stage of its replicative program. Recent 
reports demonstrated that keratinocyte differentiation coincides with and is 
induced by an increase in expression of the acetyltransferase p300 (EP300) 
(Wong, Pickard, & McCance, 2010).  Our lab has previously identified conserved 
lysine residues in Bovine PV (BPV1) E2 that were acetylated by p300 in vitro and 
regulate its transcriptional activation capability (Quinlan, Culleton, Wu, Chiang, & 
Androphy, 2012). Of the several conserved lysines that were identified, a di-
lysine motif located in the transactivation domain was of particular interest. These 
lysines at positions 111 and 112 are conserved in more than 90% of PVs (Figure 
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1.7), including BPV1 and cancer associated ‘high risk’ HPV types 16, 18, and 31. 
Studies have shown that mutating these lysines to alanines reduced their ability 
to activate transcription and alter their nuclear localization (Quinlan, Culleton, 
Wu, Chiang, & Androphy, 2013). 
 
In this study we examined the effect of mutating these lysines on BPV replication, 
and the effect of corresponding mutants in HPV31 E2 on the initiation of DNA 
replication. We discovered that viral replication did not tolerate the conservative 
mutation of K111 to arginine. Our data reveal that DNA unwinding by the E1 
helicase is dependent on the presence of a lysine at position 111 in E2.   
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Figure 1.7 
 
 
 
Figure 1.7 Sequence alignment of PV E2 and location of K111. Lysine 111 is 
a highly conserved amino acid residue is most PVs, including high and low risk 
HPVs and non-human PVs. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Materials  
 
2.1.1 Cell culture, Plasmids, Reagents 
 
C33A and HeLa (ATCC), HEK293TT (J. Schiller, C. Buck), H1299 (Giaccone et 
al., 1992), CV-1 Douglas Lowy), and J23T3 (H. Green) were maintained in 
Dulbecco’s Modified Eagle Medium (Life Technologies) supplemented with 10% 
FBS (Atlas Biologicals) and 100 U/ml penicillin/streptomycin (Life Technologies). 
Specific information about all cell lines used in this study can be found in Table 
A-5. 
 
Spontaneously immortalized keratinocyte cell line (NIKS) were co-cultured in F-
Media (Allen-Hoffmann et al., 2000) with mitomycin-C treated J23T3.  
 
Primary HFKs were harvested from donated human neonatal foreskins, and were 
maintained in KSFM (Life Technologies) supplemented with 100 U/ml 
penicillin/streptomycin.  After transfection they were cultured on feeder cells in E-
media. 
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F-Media 
3 parts Ham’s F12 nutrient mix (Life Technologies) 
1 part Dulbecco’s Modified Eagle Medium (Life Technologies) 
5% FBS (Atlas Biologicals) 
400 ng/ml hydrocortisone (Sigma) 
5µg/ml insulin (Sigma) 
0.18 mM adenine (Sigma) 
0.1 nM cholera toxin (Sigma) 
100 ng/mi epidermal growth factor (EGF) (Life Technologies) 
100 U/ml penicillin/streptomycin (Life Technologies) 
 
E-Media 
1 parts Ham’s F12 nutrient mix (Life Technologies) 
3 part Dulbecco’s Modified Eagle Medium (Life Technologies) 
5% FBS (Atlas Biologicals) 
400 ng/ml hydrocortisone (Sigma) 
5µM transferrin (sigma) 
5 µg/ml insulin (Sigma) 
0.18 mM adenine (Sigma) 
0.1nM cholera toxin (Sigma) 
100ng/mi epidermal growth factor (EGF) (Life Technologies) 
100 U/ml penicillin/streptomycin (Life Technologies) 
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Southern blot analyses were conducted using the Brightstar BioDetect Kit 
(Ambion) and the Random Primed DNA Labeling Kit (Roche).  
 
HPV31 E2 mutant plasmids were constructed by site-directed mutagenesis 
(Aligent; Quick-Change II).  
 
HA tagged HPV31 E2 was obtained from P. Howley (Powell et al., 2010), codon 
optimized flag tagged HPV31 E2 was supplied by A. McBride (Oliveira, Colf, & 
McBride, 2006), and the HPV31 E1, pCI-RLuc, and pFLOri31 constructs were 
obtained from J. Archambault (Fradet-Turcotte, Morin, Lehoux, Bullock, & 
Archambault, 2010) (Table A-4). 
 
Antibodies used include anti-Flag M2 (Sigma Aldrich), anti-HA (HA7; Sigma 
Aldrich), TopBP1 (Bethyl), mouse anti-FLAG M2 and mouse anti-HA (Sigma 
Aldrich). Anti-Brd4 antibodies were obtained from C. Chiang, and goat anti-
mouse 594 and goat anti-rabbit 488 HRP were from the Jackson 
ImmunoResearch. Alexa Fluor antibodies were purchased from Thermo Fisher.  
 
All primer sequences for PCR. Mutagenesis, and sequencing are located in 
Tables A-1,2,and 3. 
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2.2 Methods 
 
2.2.1 Transfections  
 
Various transfection methods were utilized in this study. C33A and HeLa were 
transfected with Lipofectamine2000 at a ratio of 1:1, 293TT were transfected with 
PEI at a ratio of 1:2, and NIKs were transfected using X-tremeGene HP DNA 
Transfection Reagent (Roche) at a ratio of 1:2 DNA to transfection reagent. 
C33A cells for BPV replication assays were transfected by CaPO4 transfection.  
 
Lipofectamine2000™ transfection. 
 
Cells were transfected at 50% confluence unless otherwise specified. Plasmids 
were prepared for transfection with equivalent DNA loads for each sample. In two 
separate tubes containing 100 µl of Opti-MEM® (Life-Technologies) each, the 
plasmid mixes were added to one tube and the corresponding amount of 
Lipofectamine to the other. The tubes were incubated at room temperature for 5 
minutes, and then the contents mixed by pipetting. After 10 minutes the 
transfection mix was added to the cells. The cells were incubated at 37°C and 
5% CO2 over night, and then the transfection media was replaced with fresh 
media. 
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PEI transfection 
 
Plasmid mixes were prepared for transfection with equivalent DNA loads for each 
sample. In a tube containing 200 µl of Opti-MEM® (Life-Technologies) and PEI, 
the plasmid mixes were added and mixed by pipetting. Plasmid mixes were 
incubated at room temperature for 10 minutes, and then the transfection mix was 
added to the cells. The cells were incubated at 37°C and 5% CO2.  
 
Calcium Phosphate Transfection 
 
Cells were seeded for experiments overnight and were transfected at ~50% 
confluence. The cells were given fresh growth media 3 hours prior to transfection 
and the reagents were thawed to room temperature. Two tubes were prepared 
for each transfection; one containing HEBS and the second DNA and CaCl2 
diluted in H2O. The DNA tube contents were thoroughly mixed, then the HEBS 
was added to the DNA tube drop-wise while air is bubbled through the sample for 
mixing.  The tubes were then incubated at room temperature for 30 minute 
before adding to the cells.  
 
X-tremeGENE HP transfection 
 
The transfection reagent was allowed to thaw at room temperature prior to 
transfection. The reagent was diluted in Opti-MEM® and the DNA was added to a 
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ratio of 1 µg plasmid DNA to 100 µl medium. Samples were incubated at room 
temperature for 15 minutes and then added directly to cells in growth medium.  
 
Amaxa®Human Keratinocyte Nucleofector® Transfection 
 
Keratinocytes were passaged at 70% confluence 4 days prior to transfection. 
Plates of culture (E media) with J2 feeders were prepared for each transfection. 
The cells were trypsinized and the trypsin was neutralized with trypsin inhibitor. 
The cells were collected and centrifuged at ~200g at room temperature. The 
supernatant was discarded and the pellet was resuspended in 100 µl of 
Nucleofector® solution, then combined with 100 µl DNA (in water). The mixture 
was transferred to a cuvette and electroporation was conducted with a 
Nucleofector® device under the high efficiency setting for keratinocytes. The 
cells were immediately transferred to E media.  
 
Nucleofector® Solution  
82 µl Nucleofector® Solution  
18 µl supplement 
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2.2.2 Keratinocytes 
 
2.2.2.1 Harvesting Keratinocytes  
 
Foreskins were collected in antibiotic solution, and stored at 4°C until harvesting. 
The tissue was cut into strips, and the subcutaneous layer of fat and hypodermis 
were removed with tweezers and a scalpel. The strips were placed epidermis 
side down into a sterile dish with collagenase dispase solution. 5 ml of 
Keratinocyte Serum Free Media (KSFM) were added to the dish and the entire 
dish was wrapped in plastic and stored at 4°C overnight. After incubation the 
epidermis was peeled off using tweezers and transferred into a dish of KSFM. 
The tissue was minced using a scalpel, added to a tube containing Trypsin/EDTA 
(Life Technologies), and incubated at 37°C for 45 minutes with frequent agitation. 
The trypsin was neutralized using trypsin inhibitor (Life Technologies) and the 
tube was centrifuged at ~200g for 5 minutes. The supernatant was discarded and 
the cells were resuspended in KSFM. The cells were then plated and incubated 
at 37°C.  
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Antibiotic Solution (store at 4°C) 
1% penicillin/streptomycin 
250 ng/ml amphotericin B 
 
 
Antibiotic Dispase Solution  
1% penicillin/streptomycin 
250 ng/ml amphotericin B 
1% dispase solution 
 
2.2.2.2 Keratinocyte culture 
 
Primary cells (HFKs) are maintained in KSFM and passaged at ~70% 
confluence. Primary HFKs are passaged lightly, always maintaining a confluence 
between 30 and 70%. Cells are trypsinized with 0.05% trypsin/EDTA and this is 
neutralized with trypsin inhibitor (never a full serum growth medium), and cells 
are frozen in KSFM supplemented with 1% DMSO. HFK cell lines containing 
HPV31 genomes are maintained in either E or F-media and co-cultured with 
feeder cells. Feeder cells are replenished every 72 hours by trypsinizing the plate 
at room temperature for 1 minute, then aspirating the cells off and replacing them 
with new feeders and fresh media. Feeder cells are J23T3 (mouse epithelial 
fibroblasts) that are treated with mitomycin C (2 µg/ml for 6 hours). 
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Transfections of Keratinocytes are conducted by electroporation or XtremeGene-
HP in the case of the NIKS. Primary keratinocytes are maintained on feeders in 
E-media following transfection and are allowed to proliferate for 72 hours prior to 
any selecting.  
 
2.2.3 DNA Extraction and Purification 
 
2.2.3.1 Hirt Extraction 
 
Low molecular weight DNA is extracted from mammalian cells by Hirt extraction 
(Hirt, 1967). Cells on plates were rinsed with 1x PBS and harvested by scraping 
into a 1.5 ml tube. The cells were centrifuged at 4000 rpm for 5 minutes and the 
supernatant discarded. The cell pellet was resuspended in Hirt extraction buffer; 
SDS and EDTA were added first and incubated at room temperature for 5 
minutes before adding the NaCl. The samples were incubated at 4°C overnight. 
The following day, the high molecular weight DNA was removed by centrifugation 
at maximum speed for 30 minutes at 4°C. DNA was purified from the supernatant 
by phenol:chloroform extraction. 
 
Hirt extraction Buffer: 
0.6% SDS 
10 mM EDTA 
1 M NaCl 
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2.2.3.2 Genomic DNA Extraction 
 
Cells on plates were rinsed with 1x PBS and harvested by scraping into a 1.5 ml 
tube. The cells were centrifuged at 4000 rpm for 5 minutes and the supernatant 
discarded. The cell pellet was then resuspended in Extraction buffer and 
incubated in a 50°C water bath overnight. DNA was extracted from the samples 
by phenol:chloroform extraction.  
 
 
Extraction buffer: 
100 mM NaCl 
10 mM TrisCl, pH 8 
25 mM EDTA, pH 8 
0.5% SDS 
0.1 mg/ml proteinase K 
 
2.2.3.3 Phenol:Choloroform DNA Extraction 
 
Samples were brought to a volume of 500 µl and added to an equal volume of 
phenol:chloroform:isoamyl alcohol (25:24:1) (Sambrook & Russell, 2006). The 
tubes were vortexed for 1 minute and centrifuged at 14000 g for 15 minutes at 
room temperature. The aqueous (top) layer was transferred by pipette to a fresh 
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microfuge tube and the process was repeated. After the second centrifugation, 
the top layer was transferred to a tube containing 500 µl of chloroform, vortexed 
and separated by centrifugation.  
 
 
2.2.3.4 Ethanol Precipitation 
 
This process usually follows the phenol:chloroform extraction procedure. The 
sample was added to 100% ethanol and 3 M sodium acetate at a ratio of 1:2:0.1. 
The samples were vortexed and incubated at -20°C for 1-2 hours. DNA was 
pelleted by centrifugation at 14000 g and 4°C for 30 minutes. The supernatant 
was discarded, and incubating the open tubes at room temperature for 10 
minutes evaporated any residual ethanol.  The DNA was then resuspended in TE 
or water.  
 
2.2.4 Viral Replication Assays  
 
2.2.4.1 Luciferase 
C33A cells were seeded at a density of 25000cells/well 24 hours prior to 
transfection into 96-well clear bottom plates (Corning). Luciferase based 
replication assay as previously reported (Fradet-Turcotte et al., 2010). 10 ng 
each of HPV31 E1, E2 and 2.5 ng pFLORI31/pFLORIBPV-1 constructs were co-
transfected into C33As in a 96 well plate, 0.5 ng of pCI-RLuc construct was 
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transfected per well to normalize for transcriptional activation of the firefly 
luciferase gene, and the total DNA quantity was adjusted to 100 ng with pCI. 
Cells were incubated in the transfection media overnight then media was 
replaced with normal growth media (DMEM). Cells were lysed in Dual-Glo 
luciferase reagent (Promega) 72 hours post transfection and both firefly and 
renilla luciferase activities were determined using the PHERAStar FS (BMG 
Labtech). Firefly luciferase activity was normalized to renilla luciferase activity 
and the E2 control for each sample.  
 
2.2.4.2 Southern Blot 
 
Southern Blot analysis was conducted by a protocol derived from (Brown, 2001). 
C33A cells were transfected at 50% confluence with BPV-LCR, E1, and E2 
plasmids; 0.5, 3, and 1µg respectively. 72 hours after transfection the cells were 
harvested by scraping. Episomal DNA was obtained by Hirt extraction at 4°C 
overnight. Samples were centrifuged at maximum speed in a microcentrifuge for 
30 minutes at 4°C. The Supernatants were collected, and DNA was collected by 
phenol chloroform extraction (phnenol:chloroform:isoamylalcohol 25:24:1). 
Replicates of the samples were digested with BamH1 and Dpn1, and run on a 
0.8% argarose gel. The DNA gel was rinsed in 2x SSC and transferred overnight 
to BrightStar®-plus membrane in alkaline transfer buffer. The DNA was UV 
crosslinked to the membrane, then rinsed in 2x SSC. The membrane was 
blocked in hybridization buffer with heat denatured salmon sperm DNA at 65°C 
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for ~4 hours. Non-radioactive southern probes were made as instructed with the 
BrightStar® BioDetect™ Kit using the linearized BPV1-LCR plasmid. After 
blocking the membrane was placed in fresh hybridization buffer and heat 
denatured probe, and incubated overnight at 68°C. The membrane was prepared 
for imaging using the commercial buffers from the kit and accompanying 
protocols.   
 
In the case of HPV31 stable cell lines, DNA was harvested by scraping, low 
molecular weight DNA was obtained by Hirt extraction, and the same steps were 
followed to prepare the membrane. Radioactive (α-32P) probes were prepared 
with the Random Primed DNA Labeling Kit (Roche) according to the instructions. 
25 ng linear HPV31 genome in 9 µl H2O were denatured at 95°C for 10 minutes 
then immediately moved to an ice bath. dNTPs ( dATP, dGTP, dTTP; 1 µl each), 
commercial reaction mixture, 50 µCi [α-32P]dCTP (5 µl) and Klenow enzyme (1 
µl) were added to the DNA solution and mixed thoroughly. The mix was 
incubated for 1 hour in a 37°C water bath. The reaction was stopped by heating 
to 65°C for 10 minutes. The probe was then purified using a DNA purification 
column. The probe mixed with fresh APH, added to the membrane, and was 
incubated for 48 hours at 65°C. The membrane was washed several times in 
SSC and the exposed to the film for 48 hours before analysis on a phosphor-
imager.  
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Alkaline transfer Buffer: 
0.4 M NaOH  
1 M NaCl 
 
Hybridization Buffer: 
5x Denhart’s solution 
5x SSC 
1% SDS 
100 µg/ml salmon sperm DNA 
 
2.2.5 Flow Cytometry 
 
C33a cells at 50% confluence were transfected with 2 µg of HPV31 E2 in 60cm 
dishes. 48 hours after transfection, the cells were harvested with 0.1% Trypsin 
EDTA, spun down and fixed in 90% ethanol. The samples were washed in PBS 
and treated with 50 µg/µl each of propidium iodide (PI) and RNase A for 20 
minutes. The samples were analyzed using a BD FACS Caliber APS flow 
cytometer (10,000 events were counted; FL2A for PI: excitation at 488 nm) and 
FlowJo software.  
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2.2.6 Immunofluorescence  
 
C33A and NIKs cells on coverslips were transfected with 2.5 ng of each plasmid. 
Cells were fixed 48 hours post transfection for 15 minutes in 4% formaldehyde 
solution in PBS, washed three times with PBS, and permeabilized in PBT (0.2% 
tritonX/PBS) for 10 minutes. The cells were blocked for 1 hour in 10% normal 
goat serum/PBT, and incubated with primary antibodies (1:5000 in 10% normal 
goat serum/PBT) overnight. The cells were washed three times and incubated 
with secondary antibodies (1:5000 in 10% normal goat serum/PBT) for one hour. 
Cover slips were washed and then mounted with VECTASHIELD antifade 
mounting medium with DAPI (Vector Labs).  
 
2.2.7 Transcriptional Repression  
 
2.2.7.1 Luciferase Assay 
 
25 ng of HPV31 E2 (wt or mutant) or empty vector control (pCI) and 100 ng 
HPV31-luc constructs were co-transfected into C33As in each well of a 12-well 
plate. 48 hours post transfection; cells were lysed and processed with the Dual-
Glo luciferase kit (Promega). Luminescence was measured using the 
PHERAStar FS (BMG Labtech).  
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2.2.7.2 HeLa repression assay 
 
HeLa cells in 6 well dishes were transfected at 50% confluence with 1 ug HPV31 
E2 (WT or mutants). 48 hours post transfection the cells were rinsed with cold 
PBS and lysed directly in plates using 1 ml TRIZOL. The cells were collected by 
scraping, and homogenized by several passes through an 18-gauge syringe. 
RNA was isolated by phase separation and resuspended in DEPC-treated water. 
cDNA synthesis was conducted with the SuperScript III First-Strand Synthesis 
System (Thermo Fisher Scientific) and RNA was analyzed by quantitative PCR 
using HPV18 E6 and actin primers. Figure 2.1 illustrates the mechanism of E2 
repression of the E6 gene. The oligos were obtained from Integrated DNA 
Technologies®.  
 
HPV18 LCR F04: 5’ – TGG TGT TTG CTG GCA TAA TC – 3’ 
HPV18 LCR R04: 5’ – TCC GTG CAC AGA TCA GGT AG – 3’ 
HeLabActin F01: 5’ – GGA CAT CCG CAA AGA CCT GT – 3’ 
HeLabActin R01: 5’ – CCA GGG CAG TGA TCT CCT TC – 3’  
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Figure 2.1 
 
 
Figure 2.1 HeLa repression assay. Illustration of the concept behind the HeLa 
repression assay as used for measuring E2 transcriptional repression. Re-
introduction of E2 into HeLa cells leads to reduction in E6 transcripts.  
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2.2.8 Co-Immunoprecipitation  
 
293TT cells were co-transfected with plasmids expressing a codon optimized and 
flag tagged HPV31 E2 and the protein of interest (Sakakibara, Mitra, & McBride, 
2011). The cells were harvested 48 hours post transfection and lysed in 1 ml 
NP40 buffer (0.5% NP40, 50mM Tris, 150 mM NaCl) for 10 minutes on ice. 100 
units of Benzonase endonuclease were added to each sample, and they were 
rotated at 4°C for 30 minutes. Samples were centrifuged, and supernatants were 
collected in fresh tubes for immunoprecipitation and inputs. For protein binding 
the samples were rotated overnight at 4°C with either antibody conjugated 
beads, or Sepharose A/G beads and ~1µg of antibody. The beads were washed 
five times with NP40 lysis buffer and resuspended in SDS sample buffer. The 
samples and their respective inputs were then analyzed by western blot. 
 
 
 
2.2.9 Chromatin Immunoprecipitation 
 
C33A cells were transfected with plasmids expressing HPV31 E1, E2 and the 
HPV31 origin of replication (PFLOri31). 48 hours post transfection, the cells were 
crosslinked in 1% para-formaldehyde for 10 minutes at room temperature. The 
cells were rinsed with cold PBS and the crosslinking stopped with 0.125 M 
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glycine. The plates were rinsed with cold PBS 3 times, and the samples were 
collected by scraping. These samples were processed using the ChIP-It 
Enzymatic Shearing kit (Active Motif). The DNA from the samples and their 
inputs (Figure 2.2) were analyzed by quantitative PCR using primer pairs 
designed against the HPV 18 or 31 LCR.  
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Figure 2.2 
 
 
 
Figure 2.2 Chromatin Immunoprecipitation. Illustration of the ChIP assay 
showing both IP and input controls.  
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2.2.10 Formaldehyde Assisted Isolation of Regulatory Elements (FAIRE) 
 
Plasmids expressing HPV31 E2 and E1, along with a plasmid containing the LCR 
of HPV31 (PFLOri31), were transfected into C33A cells (Figure 2.3). Cells were 
harvested 48 hours post transfection. One replicate of each sample was 
harvested immediately by scraping in to cold PBS, and the other was 
formaldehyde crosslinked with 1% para-formaldehyde for 10 minutes at room 
temperature. The crosslinking was stopped with 0.125 M glycine for 1 minute, 
and after washing three times with cold PBS, the samples were collected by 
scraping. After shearing with the ChIP-It Enzymatic Shearing kit (Active Motif), 
the chromatin was extracted by phenol-chloroform extraction followed by ethanol 
precipitation, and resuspended in TE buffer. The crosslinked and respective 
uncrosslinked control samples were analyzed by quantitative PCR with primer 
sets designed for the HPV31 replication origin (DeSmet et al., 2016). 
 
LCR primers used for FAIRE:  
 
LCR3 F:  5’ – GTT CTG CGG TTT TTG GTT TC - 3’ 
LCR3 R:  5’ – TGT TGG CAA GGT GTG TTA GG – 3’ 
LCR4 F:  5’ – AAA GTG GTG AAC CGA AAA CG – 3’ 
LCR4 R:  5’ –CAT GCA ATT TCC GAG GTC TT – 3’   
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Figure 2.3 
 
 
 
Figure 2.3  FAIRE Assay. This diagram illustrates the concept and protocol for 
FAIRE assay used to analyze nucleosome structure at the replication origin.   
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2.2.11 Formation of E1 double hexamer in vivo 
 
C33A cells were transfected with different combinations of pFLORI31, HPV31 
E1, and E2. 48 hours post transfection, the media was aspirated off of the cells, 
and they were rinsed with PBS and fixed with 4% para-formaldehyde for 5 
minutes at room temperature. The formaldehyde was removed and the plates 
were rinsed twice with cold PBS. The cells were collected into 1.5 ml tubes by 
scraping and lysed with NP40 lysis buffer for 10 minutes on ice prior to adding 
100 units of Benzonase to each sample and rotating at 4°C for 1 hour. The 
samples where then immunoprecipitated (see 2.2.8) with an anti-HPV16 E1 
antibody that recognizes HPV31 E1. Protein samples were run on a 4-15% 
gradient gel (BioRad), and analyzed by western blot analysis with anti-E1 and 
flag antibodies.  
 
2.2.12 HPV31 Stable Cell Lines 
 
2.2.12.1 HPV31 Whole Genome Cloning  
 
E2 K111 mutations were inserted into the 10.3 Kb genome by a method that 
required moving an E2 fragment into a smaller temporary plasmid, site directed 
mutagenesis, and then shuttling the fragment back into the larger plasmid (Figure 
2.4). The pBR322 HPV31 plasmid was digested with XbaI:HindIII, HindIII:PvuI, 
and XbaI:PvuI. pUC18 was digested with HindII:XbaI at the multiple cloning site 
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(MCS). The digests were all run on a 1% agarose gel and bands were excised 
based on expected sizes of the resulting fragments. DNA was extracted from the 
gel slices with a Gel Extraction Kit (Qiagen). The DNA fragment resulting from 
the digestion of pUC18 and the XbaI:PvuI fragment from the HPV31 plasmid 
were treated with Antarctic phosphatase prior ligation procedures. The HPV31 
HindII:XbaI fragment was inserted into pUC18 using T4 ligase overnight at 16°C. 
The DNA was transformed into DH5α cells the following day, streaked onto 
ampicillin plates, and incubated at 37°C overnight. Colonies were picked the 
following day and grown in 4 ml cultures. DNA was extracted and purified from 
bacterial cultures with a [plasmid mini-prep kit (Life Technologies) according to 
manufacturer’s instructions. The DNA was run of an agarose to confirm insertion 
by size.  
 
Mutations at K111 were produced by site directed mutagenesis, and mutants 
were confirmed by sequencing. The HPV31 mutant fragment and pUC18 are 
equal in size, so the plasmids were digested out of the pUC18 plasmid with 
HindIII:XbaI:PvuI to produce only one fragment at the desired size. The DNA was 
run on a gel and the band excised followed by a DNA extraction with the gel 
purification kit. To reconstitute the HPV31 plasmid, the three DNA fragments 
were ligated using T4 ligase overnight. DNA was transformed into DH5 α cells 
the following day, streaked onto ampicillin plates, and incubated at 37°C 
overnight. Colonies were screened for presence of mutations at K111.  
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Figure 2.4 
 
 
 
Figure 2.4  Cloning strategy for the HPV31 whole genome mutants. Cloning 
the K111 mutants into the whole genome plasmid was a multistep process. It 
required moving a portion of E2 into a temporary vector, site-directed 
mutagenesis, and a 3-way ligation to re-constitute the large plasmid. 
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2.2.12.2 Site Directed Mutagenesis 
 
Site directed mutagenesis was conducted using the QuickChange II Site-
Directed Mutagenesis Kit (Agilent Technologies) according to manufacturer’s 
instructions. The PCR reaction was set up as below and the parameters in Table 
2.1: 
 
Strand Synthesis Reaction 
5 µl 10x reaction buffer 
5 ng/µl plasmid DNA 
100 ng/µl of each primer 
1 µl dNTP mix 
H2O to bring the total volume to 50 µl. 
1 µl of PfuUltra HF DNA polymerase (added last) 
 
PCR parameters: 
Table 2.1 
# of Cycles Temperature (°C) Time (sec) 
1 95 30 
16 95 30 
55 60 
68 300 
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The PCR products were cooled to 37°C, and then digested with DpnI (1 µl was 
added directly to the PCR product at 37°C). After digestion the products were 
transformed into bacteria. Following extraction and purification the K111 
mutations in the resulting DNA were confirmed by sequencing. 
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CHAPTER 3 
RESULTS 
 
3.1 K111 is necessary for transient viral replication  
 
Two lysine residues, K111 and K112, are highly conserved among human and 
animal PVs (Figure 1.7). We previously demonstrated the requirement of K111 
for BPV1 E2 transcriptional activation (Quinlan et al., 2012). While E2 is known to 
bind and localize the E1 helicase to the replication origin, which is flanked by 
high affinity E2 binding sites, additional role(s) for E2 in DNA replication have not 
been elucidated.  We began testing both BPV and HPV-31 E2 K111 and K112 
substitution mutants for stimulation of E1 dependent viral replication following co-
transfection with E1 and the PV origin containing luciferase reporter construct. 
This di-lysine (K111 & K112) motif has been previously studied in BPV1, and 
mutation at both lysines resulted in a decreased viral replication, whereas a 
mutation at K111 alone (K111R) caused a more severe reduction in viral 
replication (Abroi, Kurg, & Ustav, 1996; Brokaw, Blanco, & McBride, 1996).   
 
To further explore the role(s) of E2 K111/K112 in viral replication, we used the 
luciferase system and southern blots to measure transient replication of K111 
and K112 mutants as well as a number of other conserved lysines that we have 
previously reported as targets for p300 acetylation (Figure 3.1). The southern blot 
results initially showed that K111R mutant was able to support viral replication, 
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however, a further analysis of pre-digested samples indicated variation of E1 and 
E2 levels among samples. Due to these inconsistencies with the southern blot 
analysis, we used a luciferase based replication assay to quantifiably measure 
transient replication (Figure 3.2). Compared to wild type BPV E2, mutations at 
both lysines had deleterious effects on replication, while K112 resulted in a 
reduction and K111R completely abrogated transient DNA replication (Figure 
3.2).  The W145R mutant was included in the luciferase assay as a negative 
control, since this g-protein pathway supressor 2 (GPS2) binding deficient 
mutation has been described as replication defective (Breiding, Grossel, & 
Androphy, 1996). 
 
The conservative arginine mutant as well as alanine mutation were tested in 
HPV31 E2. The results indicate that mutations that prevent acetylation (alanine) 
at K111 or mimic a deacetylated lysine (arginine) do not induce replication 
(Figure 3.3).  However, the HPV31 K111 glutamine (Q) mutation, which 
resembles an acetyl lysine, stimulated replication to levels that surpassed wild 
type E2.  We ensured that the abrogation of replication from the K111R mutant 
HPV31 E2 protein was not due to reduced cell viability (Figure 3.4). These 
experiments also demonstrated that while replication is affected by K112 in the 
context of BPV1 (Quinlan et al., 2012), mutations at this position in HPV31 E2 did 
not exhibit a similar dependence (Figure 3.3). 
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Figure 3.1 
 
 
 
 
Figure 3.1 Replication of BPV-1 E2 lysine mutants. Southern blot analysis of 
lysine to arginine mutants of BPV-1 E2, indicating the expression of E1, E2 and 
the quantity of replicated LCR plasmid. Inconsistent levels of E1 and E2 plasmid 
were evident in the undigested lanes.   
E2 
 
 
 
E1 
LCR 
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Figure 3.2 
 
 
 
 
 
Figure 3.2 BPV-1 E2 K111 mutants affect transient replication. C33A cells 
were co-transfected with BPV-1 E2 K111 mutants, pFLORI-BPV-1, and pRRL. 
Results were normalized to renilla luciferase and E2 transcription and presented 
as fold over E1 only control. *p <0.05, ** p <0.005   
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Figure 3.3 
 
 
 
Figure 3.3 Transient replication activities of HPV31 E2 K111 mutants. C33A 
cells were co-transfected with HPV31 E2 K111 mutants. E2 mutants were co-
transfected with pFLOri31. The luminescence was normalized to renilla luciferase 
and the respective background E2 luminescence. Each of the samples was 
normalized to their respective control without E1 to cancel out any background 
effect. * p <0.05, ** p <0.005  
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Figure 3.4 
 
 
Figure 3.4 Effects of K111 mutations on cell cycle. The effect of K111R 
mutant on cell viability and cell cycle was determined by flow cytometry. 
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3.2 Nuclear Localization of E2 occurs Independently of K111 
 
Since K111 of E2 is crucial for viral replication, we further investigated whether 
mutation(s) at K111 also affects nuclear localization. Though unlikely due to 
arginine preserving the charge at 111, a possible explanation for this loss of 
activity is that K111 is located near the putative nuclear localization sequence 
(NLS) within the trans-activation domain of E2 (Figure 1.4). Deletion mutants in 
this region of BPV1 are reported to cause E2 to be diffused throughout the cell 
rather than nuclear (Skiadopoulos & McBride, 1996).  
 
To determine if the mutants demonstrate the same effect in HPV31, we used 
immunofluorescence technique and observed nuclear localization of K111R 
mutant compared to wt-E2. A common cell line used in immunofluorescence 
experiments was a monkey kidney cell line CV-1. E2 K111R had an adverse 
effect on the nuclei of transfected CV-1 cells. This effect was not observed with 
wt or K111Q. The nuclei of K111R cell developed a fragmented appearance 
(Figure 3.5). To study this phenotype we repeated the experiment with other cell 
lines (C33A, NIKS, and H1299s), and also observed the nuclei of HFKs 
transfected with the HPV31 genome. Our results indicated that this phenotype is 
cell line specific. 
 
In transfected C33A, NIKS, and H1299 cells, E2 nuclear localization was 
unaffected by the K111 mutations (Figure 3.4). These results clearly indicate that 
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mutations at K111 do not inactivate the putative NLS and E2 remains nuclear. 
This differs from what was observed with BPV-1 E2 where mutations at K111 
resulted in a sub-population of E2 that was localized to the cytoplasm (Quinlan et 
al., 2013). 
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Figure 3.5 
 
               WT                          K111R                        K111Q 
 
 
Figure 3.5 K111 mutants do not affect E2 localization. CV1, C33A, NIKS, and 
H1299 cells were transfected with HPV31 E2wt and the K111 mutants. The cells 
were incubated with HA7 antibody 48 hours post transfection and analyzed by 
immunofluorescence for E2 (red) and DAPI (blue). Nuclei of primary HFKs stably 
transfected with HPV31 wt and mutant genomes are observed (bottom row).  
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3.3 Mutations of HPV31 E2 K111 facilitate transcriptional repression.  
 
Although K111 is located in the transactivation domain of E2 and not the C-
terminal DNA binding region, it may still affect E2 binding to chromatin DNA. 
Chromatin immunoprecipitation was used to test whether K111 is involved in 
DNA binding activity of E2 (Figure 3.6). Our results showed that both HPV31 E2 
K111R and K111Q were able to bind near the origin with no significant 
differences compared to wild type E2.  
 
Due to similar results on the effect of the K111 mutants on replication in BPV1 
and HPV31, we investigated the transcriptional activities of the K111 mutants. 
Unlike BPV E2 protein’s strong activation, the HPV31 E2 protein acts as an 
efficient repressor of viral gene transcription (Bernard et al., 1989; Romanczuk et 
al., 1990; Thierry & Howley, 1991). To examine the effects of mutating K111 on 
E2 transcriptional repression, we used an HPV31-luciferase assay.  
 
C33A cells were transfected with plasmids expressing HPV31 E2, and a plasmid 
containing a portion of the HPV31 LCR containing the E2 binding sites and p97 
promoter upstream of a firefly luciferase gene. Expression of wild type E2 levels 
was measured to validate the concentrations of E2 used in the assay (Figure 
3.7). I found that the most robust repression effect occurs with low levels of E2. 
As the quantity of E2 transfected into the cells was increased we observed a 
dose-dependent increase in transcription due to a squelching effect. Squelching 
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is a process where a transcription factor inhibits the expression of another gene 
by directing critical factors away from their targets. E2 in excess may lose its 
ability to repress transcription due to E2 protein sequestering other transcriptional 
co-factors away from the E2 DNA binding sequences.  BRD4 is a potential 
suspect in this phenomenon. Since BRD4 is integral to HPV E2 transcriptional 
repression (McPhillips et al., 2006), free E2 sequestering BRD4 away from E2 
bound near the p97 promoter may cause de-repression (Figure 3.7). We selected 
a low quantity of E2 for the repression luciferase assay. K111R, K111Q, and 
K111A mutants repressed transcription at levels similar to those of wild type E2 
(Figure 3.8). This indicates that K111 is not necessary for HPV31 transcriptional 
repression.  
 
The luciferase results with C33A cells were also confirmed by a transcriptional 
repression assay with HeLa cells in order to determine if the K111 mutants were 
able to access chromatin. In the integrated HPV18 genome of HeLa cells, E2 
represses transcription of the early promoter resulting in a reduction of E6 
transcripts. HeLa cells were transfected with either a vector control or HPV31 E2 
plasmid. When compared to the normal HeLa negative control, cells transfected 
with wild type E2 as well as the E2 mutants all repressed transcription of the E6 
gene (Figure 3.9). Together with the ChIP, our data suggest that the K111 
mutants are able to access E2 binding sites in the chromatin context (Table 3.1).  
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Figure 3.6 
 
 
Figure 3.6 HPV31 E2 K111 mutants (K111R & K111Q) bind to the origin 
DNA. C33A cells were co-transfected with 31-Fluc and HPV31 FLAG-E2 wt or 
K111 mutants. The amount of E2 at the origin was determined by ChIP. * p <0.05 
compared to E1 in the absence of E2. 
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Figure 3.7 
 
 
 
 
Figure 3.7 E2 most efficiently represses transcription at low 
concentrations. C33A cells were transfected with 31-FLuc and HPV31 wt 
FLAG-E2 at increasing amounts of transfected E2. Luciferase was measured by 
luminometry and repression was presented relative to baseline transcription.  
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Figure 3.8 
 
 
 
 
 
Figure 3.8 HPV31 E2 lysine 111 mutants repress transcription. C33A cells 
were co-transfected with 31-FLuc and HPV31 FLAG-E2 wt or the K111 mutants. 
Luciferase was measured by luminometry and repression was presented as a 
fraction of baseline transcription. * p <0.05  
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Figure 3.9 
 
 
 
Figure 3.9 HPV31 E2 lysine 111 mutants repress transcription at the HPV18 
early promoter. HeLa cells were transfected with HPV31 wt HA-E2 or the 
mutant (K111R or K111Q), and harvested after 48 hours. E6 transcripts 
quantified by q-PCR and presented as a percentage transcription in the absence 
of E2. * p <0.05  
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Table 3.1 
 
HPV31 E2 Transcription 
Repression 
Nuclear 
Localization 
Viral Replication 
wt + + + 
K111R + + - 
K111Q + + ++ 
 
 
Table 3.1 Summary of HPV31 E2 functional assays. HPV31 E2 is localized to 
the nucleus and represses transcription regardless of the status of K111. K111R 
is replication defective and the K111Q acetylation mimic shows enhanced 
replication. 
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3.4 HPV31 E2 interactionS with host factors are not perturbed by mutations 
at K111 
 
E2 interacts with a large number of host factors, some of which have adverse 
effects on replication when binding is abrogated.  Potentially p300 acetylation at 
K111 may be required for recruiting a necessary host factor. We investigated a 
selection of these co-factors to determine whether E2 K111R impeded binding 
and resulted in a loss of replication function (Figure 3.10), and a summary of the 
results can be found in Table 3.2.  
 
In the BPV1 system, interaction between E2 and Brd4 has been shown to be 
critical for E2 transcriptional activation and repression functions. The HPV16 E2 
Brd4 binding deficient mutant R37A/I73A is also defective in viral replication 
(Wang, Helfer, Pancholi, Bradner, & You, 2013). Brd4 is known to bind to the E2 
N-terminal transcriptional activation domain, and localizes to replication foci 
during the initiation of viral replication before being displaced from actively 
replicating origins (Sakakibara et al., 2013; Wang et al., 2013). There are three 
specific regions of Brd4 reported to potentially interact with E2 (McBride & Jang, 
2013); CTM, BID, and PDID (S. Y. Wu et al., 2016). The interaction of HPV31 E2 
was investigated by co-immunoprecipitation experiments with each of the Brd4 
binding regions (Figure 3.11). A mutation at K111 of E2 had no effect on Brd4 
CTM binding. We observed differences in binding to BID and PDID according to 
our co-immunoprecipitation experiments; however, these differences do not 
	 76 
correlate with the loss of activity with K111R and the enhanced activity of K111Q. 
The variation of protein levels may be resultant from the expression levels of the 
protein. 
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Figure 3.10 
 
 
 
Figure 3.10 Acetylation of E2 K111 on its interaction with co-factors. A 
proposed mechanism shows that p300 acetylation of E2 is involved in interaction 
with key E2 binding partners.  
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Figure 3.11 
 
Figure 3.11 HPV31 E2 K111 mutants maintain interactions with Brd4. 
Human 293TT cells were co-transfected with HPV31 FLAG-E2 and plasmids 
expressing BRD4 fragments CTM, BID, and PDID. BRD4 fragments and E2 
proteins were immunoprecipitated using GST antibody and detected by western 
blotting. BRD4 (fragments) co-IP relative to E2 immunoprecipitated was 
calculated by densitometry and presented graphically.   
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The AMF1/GPS2 protein is another factor known to interact with E2 proteins. A 
binding deficient mutant of BPV1 E2, W145R, is also transcription and replication 
defective (Breiding et al., 1997; Peng et al., 2000). We investigated the 
interaction of the HPV31 E2 mutants with AMF1/GPS2 by co-
immunoprecipitation and found that the K111 mutants interacted with GPS2 
(Figure 3.12). Interestingly, we also found that the E2 mutants differentially 
affected the expression of GPS2. K111Q transfected cells showed higher levels 
of GPS2 while K111R cells showed reduced levels when compared to cells 
transfected with wild type E2. The reason for the fluctuations of GPS2 levels is 
unknown.  
 
Topoisomerase II-binding protein 1 (TopBP1) is involved in DNA damage 
response and DNA replication (Makiniemi et al., 2001). TopBP1 influences viral 
replication (Kanginakudru, DeSmet, Thomas, Morgan, & Androphy, 2015), and 
co-localizes with PV E2 at viral replication origins as part of a DNA damage 
response (Boner et al., 2002; Reinson et al., 2013).  TopBP1 complexes with 
HPV E2 and is important for establishing the copy number of viral genomes 
(Donaldson et al., 2012), and it also increases replication and transcriptional 
activities of E2. We investigated the TopBP1 interaction with HPV31 E2 and the 
effects of the K111 mutants by co-immunoprecipitation (Figure 3.13). Both 
K111R and K111Q bound TopBP1 in a similar manner to wild type HPV31 E2.
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Figure 3.12 
 
 
Figure 3.12 HPV31 E2 K111 mutants maintain interactions with GPS2. 
Human 293TT cells were co-transfected with HPV31 FLAG-E2 and HA-GPS2. 
HPV31 E2 protein IP was executed with M2 antibody, and blotted with HA7 and 
M2 antibodies. GPS2 co-IP relative to E2 immunoprecipitated was calculated by 
densitometry and presented as a western blot and graphically.   
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Figure 3.13 
 
 
 
Figure 3.13 HPV31 E2 K111 mutants maintain interactions with TopBP1. 
293TT cells were transfected with HPV31 FLAG-E2 followed by E2 protein 
immunoprecipitation with M2 antibody. Amounts of endogenous TopBP1 co-
immunoprecipitated were determined by blotting with anti-TopBP1 and M2 
antibodies, and TopBP1 co-IP relative to E2 immunoprecipitated was calculated 
by densitometry and represented by western blot and graphically.   
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3.5 E1 protein complexes with and is recruited to the replication origin by 
the K111 mutants.  
 
An E2 mutation that reduces the interaction between E2 and E1 would likely 
have an effect on viral replication, so we investigated the E1-E2 interaction to 
determine if that was affected by the K111 mutations. Co-immunoprecipitation 
studies were conducted in 293TT cells that were co-transfected with HA-E1 and 
FLAG-E2. E1 was immunoprecipitated western blot analysis revealed that E1 
interacted with both of the E2 mutants (Figure 3.14).  
 
During initiation E2 interacts with and recruits E1 to the replication origin 
(Stenlund, 2003). Although we already established that the E2 mutants bind both 
DNA and E1 (Figure 3.6 & 3.14), we investigated the efficiency at which the K111 
mutants were able to recruit E1 to the origin. We used ChIP assays compare 
levels of E1 bound at the origin in the presence of the different E2 proteins. C33A 
cells were co-transfected with E1, E2 and pFLOri (Figure 3.15), and HeLa cells 
were co-transfected with HPV31 E1 and E2 (Figure 3.16). We found that the 
K111R and K111Q mutants both effectively recruited E1 to the viral replication 
origin in both models.  In the C33A experiment we observed a high amount of E1 
at the origin in the absence of E2 (Figure 3.15). This result is likely due to the 
ability of E1 to bind plasmid DNA at a low efficiency, in the absence of E2 despite 
the lack of sequence specificity. In the HeLa experiment, E1 needs to access 
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chromatin in order to bind at the origin, and in the absence of E2 we see 
negligible amounts of E1 at the HPV18 origin (Figure 3.16). 
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Figure 3.14 
 
 
 
Figure 3.14 HPV31 E1 binds to the mutants and stabilizes E2 protein levels. 
293TT cells were co-transfected with HPV31 FLAG-E2 and HA-E1. E1 protein 
pull down was conducted using 12CA5 antibody and analyzed by western blot. 
E2 co-IP relative to E1 immunoprecipitated was calculated by densitometry and 
represented by western blot and graphically.  
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Figure 3.15 
 
 
 
 
Figure 3.15 Both K111R and K111Q mutants can recruit E1 to the HPV31 
replication origin. C33A cells were cotransfected with PFLORI31, HPV31 HA-
E2 and FLAG-E1. ChIP assay to detect E1 at the HPV31 LCR was conducted 
with M2 antibody and LCR4 primers. * p <0.05 ** p <0.005  
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Figure 3.16 
 
 
 
 
Figure 3.16 K111 mutants recruit E1 to the HPV31 replication origin. HeLa 
cells were transfected with HPV31 FLAG-E1 and HA-E2, and the presence of E2 
at the HPV18 replication origin was determined by ChIP.  * p <0.05 
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Table 3.2 
 
HPV31 E2 TopBP1 
Binding 
E1 Binding GPS2 
Binding 
Brd4 
Binding 
Wt + + + + 
K111R + + + + 
K111Q + + + + 
 
 
Table 3.2 Summary of E2 interaction studies. E2 showed positive K111 
independent binding with each of the subset of co-factors investigated.  
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3.6 The K111R mutant of E2 reduces unwinding of the replication origin.  
 
These results with the K111R E2 protein were intriguing. Our current 
understanding of HPV replication suggests that since the K111R mutant binds 
chromatin and recruits E1 to the origin, replication initiation should be unaffected; 
however, that was not the case. During initiation the assembly of the E1 double 
hexamer follows the recruitment of E1 to the origin by E2. To determine whether 
the E1 helicase was active, a FAIRE assay was modified to infer DNA unwinding 
at the replication origin. Faire assays are typically used to identify active 
promoters by detecting sites in chromatin that are nucleosome-free (Giresi, Kim, 
McDaniell, Iyer, & Lieb, 2007; Hogan, Lee, & Lieb, 2006; Tsompana & Buck, 
2014). This principle was applied to investigate E1 + E2-mediated unwinding of 
the viral replication origin by measuring the quantity of nucleosome free origin 
DNA in the presence of wt E2 or the K111 mutants..  
 
Either E1 or E2 alone poorly supported unwinding of the replication origin-
containing DNA, but E1 co-transfected with wild type E2 resulted in 16 fold 
unwinding at the origin (Figure 3.17). The E2 K111R mutant failed to reduce 
nucleosome occupancy at the viral origin, suggesting that E1 helicase activity is 
restricted by this mutation (Figure 3.17). Surprisingly, however, the K111Q 
mutant supported origin unwinding activity 21-fold higher than E1 alone, which is 
even higher than wild-type E2. Together, these results imply that E2 K111R did 
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not support origin unwinding, while K111Q enhanced unwinding of the replication 
origin. 
 
We corroborated the FAIRE results with a second assay. Replication protein A 
(RPA) is a host replication factor that binds to ssDNA at the origin (Loo & 
Melendy, 2004).  We therefore performed a ChIP assay in the presence of 
endogenous RPA (Schuck & Stenlund, 2015) at the viral origin in cells co-
transfected with E1 and E2 (Figure 3.18). K111R abrogates the helicase activity 
of E1 resulting in low RPA binding at the origin. Interestingly, K111Q shows an 
~3 fold increase in unwinding when compared to wild-type E2. Topoisomerase 1 
(Topo1) is a protein that relieves torsional stress in supercoiled DNA during 
transcription or replication in an ATP-independent manner, and does so by 
cleaving only one strand of DNA (Champoux, 2001). Cells transfected with E1 
and cells with E2 K111R did not show recruitment of Topo1 compared to cells 
expressing wt E2 protein (Figure 3.19). In the presence of K111Q we observed a 
6 fold increase in Topo1 at the origin. These data show that E2 K111R did not 
allow origin unwinding and K111Q enhanced unwinding of the replication origin, 
and support the findings of the FAIRE assay to demonstrate that origin melting is 
the event in replication initiation that is dependent upon acetylation of K111. 
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Figure 3.17 
A 
 
B 
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Figure 3.17 Nucleosome free DNA is not found at the replication origin in 
the presence of K111R. C33A cells were transfected with FLAG-E1, FLAG-E2, 
PFLORI31. Unwinding at origin DNA was analyzed by FAIRE assay using 
HPV31 LCR primers (A) LCR3 and (B) LCR4. * p <0.05 by one-way ANOVA 
comparing to wt in absence of E1. # p<0.05 by one-way ANOVA compared to wt 
E2 + E1.   
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Figure 3.18 
 
 
 
Figure 3.18 The K111R mutant reduces RPA binding at the replication 
origin. C33A cells were transfected with FLAG-E1, FLAG-E2, PFLORI31. ChIP 
for endogenous RPA protein at the LCR used anti-RPA (70) antibody and LCR4 
primers. * p <0.05 by one-way ANOVA comparing to wt in absence of E1. # 
p<0.05 by one-way ANOVA compared to wt E2 + E1.  
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Figure 3.19 
 
 
 
 
Figure 3.19 E2 K111R failed to support recruitment of Topo1 to the 
replication origin. C33A cells were transfected with FLAG-E1, FLAG-E2, 
PFLORI31. Chip for endogenous Topo1 at the HPV31 LCR with anti-Topo1 
antibody and LCR3 primers. * p <0.05 by one - way ANOVA comparing to wt in 
absence of E1. # p<0.05  by one-way ANOVA compared to wt E2 + E1. 
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Table 3.3 
 
HPV31 E2 Viral 
Replication 
Origin 
Unwinding 
RPA 
Binding 
Topoisomerase 1 
Binding 
wt + + ++ + 
K111R - - +/- - 
K111Q ++ ++ +++ ++ 
 
 
Table 3.3 Replication origin unwinding is K111 dependent. Summary of the 
effects of K111 mutation on the functions of E2 in replication initiation. 
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 3.7 E1 Hexamers formation assay in the presence of the E2 mutants 
 
The lack of unwinding at the replication origin in the presence of K111R (Table 
3.3) indicates that the helicase activity of E1 is dependent on K111 acetylation. 
We previously concluded that the E2 mutants bind to E1 and recruit it to the 
origin, so we attempted to capture the E1 at the origin to determine the effects of 
the mutant E2 proteins on E1 double hexamer assembly. We aimed to detect 
large E1 complexes bound to origin DNA. The results of this experiment were 
inconclusive. We did not observe clear bands at the appropriate size for E1 
hexamers or double hexamers, nor was the western clear enough to attempt 
quantification or comparisons of the bands (Figure 3.20). We repeated this 
experiment using a native gel to maintain the complexes; however, under those 
conditions the antibodies failed to detect any proteins. 
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Figure 3.20 
 
Figure 3.20 Hexamer formation assay. C33A cells were transfected with 
FLAG-E1, FLAG-E2, PFLORI31. Proteins were chemically crosslinked and ran 
on a native gel electrophoresis. Immunoprecipitation and western blotting were 
conducted using HPV16 E1 antibody. The upper portion of the blot was treated 
with enhanced contrast to better visualize the large bands. 
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3.8 Episomal E2 mutant Genomes in Stable Cell Lines 
 
Several attempts were made to establish stable keratinocyte cell lines containing 
the mutant HPV31 whole genomes. Due to the large size of the pBR322 HPV31 
(Thomas, Hubert, Ruesch, & Laimins, 1999) plasmid (10.3 kb) we decided to 
shuttle a fragment containing part of the E2 gene into a smaller plasmid (pUC18) 
before performing site directed mutagenesis. Following mutagenesis the colonies 
were screened for the lysine mutants by DNA sequencing, and fragments were 
shuttled from successful clones back into the large plasmid.  Since the HPV31 
insert is the same size as linearized pUC18, the plasmids were also digested 
with PvuI, which cuts at multiple sites in pUC18.  
 
The HPV31 genomes were transfected into primary HFKs and NIKS by 
electroporation and XtremeGene HP respectively, and either selected with 
puromycin or; in the case of the primary cells, passaged until the normal cells 
senesced. The HFKs produced many clones that became immortalized following 
transfection; however, these cells either did not maintain the genomes long term 
or the genome could not be detected in them. The NIKS were more successful, 
resulting in cells that maintained the HPV31 genome which we detected by both 
PCR analysis (Figure 3.21 A) and by southern blot (Figure 3.21 B). Repeated 
rounds of transfections were needed to successfully obtain an HPV31 wt cell line, 
but we were able to develop one that demonstrated copy numbers higher than 
that of the CIN612 (Figure 3.21 C). 
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Figure 3.21 
 
 
 
 
Figure 3.21 Stable NIKS cell lines with the HPV31 whole genome maintain 
episomes. (A) PCR analysis of Hirt extracted DNA using HPV31 primers. (B) 
Southern blot of Hirt and Genomic extracts of HPV31 stable cell lines. (C) PCR of 
Hirt extracts from HPV31 stable cell lines.    
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CHAPTER 4 
DISCUSSION 
 
The role of PV E2 in replication initiation has been extensively studied; however, 
the mechanisms by which replication and copy number are regulated, and the 
specific involvement of E2 beyond E1 recruitment remain undefined. Activation of 
p97 leads to the expression of proteins E1, E2, E6 and E7 (Abroi et al., 1996; 
Sedman & Stenlund, 1995; Ustav & Stenlund, 1991), where viral early proteins 
E1 and E2 are the replication initiation proteins of PVs. The loading of E2 and its 
regulation of E1 binding, serves as a replication licensing system for viral 
replication. The E1 protein is the main viral replication protein.  It has been 
reported that in vitro, E1 alone is capable of initiating viral replication; however, 
the binding of E1 to DNA is non-specific and E2 is also required in-vivo (Loo & 
Melendy, 2004). To initiate viral replication, E2 binds to DNA in a sequence 
specific manner at sites flanking the origin of replication, and recruits E1 
monomers to the origin. When the first pair of E1 molecules binds to the 
replication origin, E2 is released from its binding sites through a process of ATP 
hydrolysis (Chen & Stenlund, 2002). More E1 molecules are recruited and form a 
double-hexameric complex at the origin that is similar to the eukaryotic Orc-Mcm 
complex. This E1 complex then serves as a helicase and unwinds the DNA to 
allow replication factors to be recruited. Without E2 serving as a viral origin 
recognition factor, the inability of E1 to bind specifically to the replication origin 
would cause inefficient and inconsistent firing of the viral origin.  
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We first identified this site through a p300 in-vitro acetylation assay. It has been 
reported that p300 levels in basal keratinocytes are low, while differentiating cells 
show high levels (Wong et al., 2010). This difference in p300 levels coincides 
with the switch of viral genomes from maintenance to vegetative amplification in 
infected cells. To explore the importance of this acetylation, we generated 
substitution mutants that represent de-acetylated and acetylated K111 (K111R 
and K111Q respectively). The acetylation deficient mutant of E2 K111R was 
observed to abrogate replication in both BPV1  and in HPV31 as shown here. 
The acetylation mimetic E2 K111Q demonstrated significantly higher levels of 
replication than wild type E2. This supports the hypothesis that acetylation at the 
111 residue is a necessary step in the initiation of replication. Furthermore, the 
K111Q result suggests that acetylation at K111 may be an integral regulatory 
step in switching the viral replicative program from maintenance to vegetative 
amplification (Reinson, Henno, Toots, Ustav, & Ustav, 2015).  
 
To determine how K111 affects replication, we analyzed and characterized the 
K111R and K111Q mutants. Since K111 is located in the putative NLS, we 
investigated the localization of E2 and found that E2 was nuclear in all 
experiments. After verifying that the K111R mutant was nuclear, we addressed 
other functions of E2. Knowing that a DNA binding deficient mutant would be 
detrimental to viral replication we conducted a ChIP of E2 at the origin that 
allowed us to directly compare the K111 mutants to wild type E2. We observed 
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no difference between the E2 proteins, which confirmed that the c-terminal DNA 
binding domain was not influenced by the K111 mutations.  HPV31 E2 serves as 
a strong repressor of transcription, and according to our results from two 
corroborating experiments; this function is maintained at levels similar to wild 
type for both mutants. HPV31 E2 ability to repress transcription results from 
binding at sites located on the TATA box of the p97 promoter, as well as 
interaction with host cell transcription factors (Demeret et al., 1997; Dostatni et 
al., 1991; Hou et al., 2000; McBride, 2013; Schweiger et al., 2007). The K111 
mutants allow transcriptional repression, which indirectly indicates that the DNA 
binding ability is unaffected and is consistent with the ChIP results.  
 
There are known cellular factors that interact with E2 and have been reported to 
directly affect E2 functions; transcriptional regulation and replication. We 
investigated the ability of the K111 mutants to interact with a subset of these 
proteins and found that K111R was not binding deficient for any of them. An 
interesting observation was that the E2 mutants exhibited differential expression 
levels. K111R was lower expressing than wild type and K111Q was expressed at 
extremely low levels when compared to wild type or K111R. The co-
immunoprecipitation experiments with the fragments of BRD4 were an exception. 
The CTM of BRD4 stabilizes E2 (Zheng et al., 2009) and that effect was clearly 
demonstrated, and the BID and PDID fragments also produced E2 stabilization to 
a lesser degree. The AMF1/GPS2 co-immunoprecipitation experiment also 
revealed something interesting. In the presence of the K111R mutant there were 
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lower levels of AMF1/GPS2 detected in the inputs; however, the results show 
that the K111R still interacts with AMF1/GPS2. Further experimentation would be 
needed to fully clarify this observation. While the expression of K111Q was low, it 
remained highly active in all of the experiments, supporting the hypothesis that 
an acetylation at K111 would result in enhanced viral replication.  
 
K111 is located in the TAD of E2, which is responsible for E1 binding (Abbate et 
al., 2004). The interaction between E1 and E2 during the initiation of replication is 
dynamic, and there is a direct interaction between E1 and the TAD of E2. We 
found that E1 binds to both K111 mutants and the E2 mutants bound DNA and 
subsequently recruited E1 to the replication origin at levels comparable to wild 
type. This interaction also demonstrates that the TAD of E2 is functional and 
therefore not mis-folded in the mutants. E2 recruitment of E1 to the replication 
origin should initiate viral replication, the first stage of which is to form the E1 
double hexamer. In order to form the E1 double hexameric helicase complex, E2 
cannot remain bound to E1 at the origin. One possible explanation is that the 
K111R mutant binds strongly to E1 and is not released, thereby hindering 
formation of the helicase complex and preventing unwinding at the origin. We 
investigated the formation of the helicase complex by determining if the origin 
becomes exposed under replication conditions by FAIRE assay. The FAIRE 
assay was modified to measure the open chromatin at the origin during 
replication conditions. Our results confirm that K111R is not capable of facilitating 
the initiation and unwinding of the replication origin.  
	 103 
 
To corroborate the results from the FAIRE we performed a ChIP for RPA at the 
replication origin. Our data reveal that there is reduced RPA at the replication 
origin with K111R and a significant increase with K111Q, suggesting a direct 
effect of E2 on the E1 recruitment of RPA to the origin. RPA is recruited to 
ssDNA by E1 and though there is a direct interaction, it is inhibited by ssDNA 
(Han, Loo, Militello, & Melendy, 1999; Loo & Melendy, 2004). Since RPA is 
necessary for DNA replication Loo et al. proposed a mechanism by which E1 
loads RPA onto ssDNA during unwinding. The role of RPA in viral replication has 
been more extensively studied in SV40. SV40 large T-antigen (Tag) has been 
reported to interact with RPA, and during replication the SV40(Tag)-RPA 
interaction is essential for assembly of the primosome complex (Melendy & 
Stillman, 1993). This specific function has not been determined for the E1-RPA 
interaction, but a similar mechanism could explain how a lack of RPA loading at 
the origin inhibits replication. 
 
Topo I has been reported to directly interact with both PV E1 and E2, both of 
which are proposed to stimulate Topo1 enzymatic activity (Clower, Fisk, & 
Melendy, 2006; Clower, Hu, & Melendy, 2006; Hu, Clower, & Melendy, 2006). 
Furthermore, E2 and Topo1 enhance E1 binding at the replication origin 
independently (Hu et al., 2006). Our ChIP results show no change in E1 
recruitment (Figure 3.15) but there is a no DNA unwinding in the presence of 
K111R, which suggests that K111R recruits E1 to the origin but does not recruit 
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or stimulate Topo1 activity. We report that E2 rather than E1 is responsible for 
recruiting Topo1 to the replication origin, and K111R does not support Topo1 
recruitment while K111Q demonstrates enhanced recruitment (Figure 3.19). 
These data propose that E2 recruitment and stimulation of Topo1 is integral to 
DNA unwinding (Figure 4.1). This is intriguing as previously the hypothesis was 
that E2 and Topo1 recruitment and stimulation were parallel and redundant 
mechanisms (Archambault & Melendy, 2013). 
 
This study characterized an acetylation site on HPV E2 that directly impacts viral 
replication. Manipulation of K111 left the E2 localization, transcription function, 
DNA binding, and E1 recruitment intact, and only affected viral replication. 
K111R was replication defective while the acetylation-mimetic K111Q enhanced 
viral replication, which lends credence to the idea that it is an acetylation at this 
site that regulates viral replication. We found that K111R abrogates replication by 
preventing the helicase activity of E1. It is possible that E2 blocks the formation 
of the E1 helicase complex, or that another factor like RPA that is involved in 
DNA unwinding is not recruited by the K111R mutant.  
 
We attempted to investigate the formation of the E1 double hexamer on the 
replication origin but the results were inconclusive. E2 recruits E1 to the origin, 
but E2 can also be inhibitory if it is not subsequently removed from DNA. Reports 
have demonstrated that chaperone proteins such as Hsp70 are required for the 
release of E2 from the E2BS (Lin, Makhov, Griffith, Broker, & Chow, 2002).  
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Experiments investigating the recruitment of these factors to replication origins in 
the presence of the E2 mutants may help to further elucidate mechanistically how 
K111 regulates replication. 
 
Further investigation of the interactions of HPV E2 K111 with factors directly 
involved in replication initiation and DNA unwinding will be necessary to further 
our understanding of how the K111 acetylation regulates replication 
mechanistically. Studying the effects of these mutants in stable keratinocyte cell 
lines during the different stages of the PV replicative cycle would also be 
necessary in furthering our understanding of how the virus is regulated. An 
interesting observation made here is that K111Q not only rescued the 
deficiencies of K111R, but this mutant outperformed wild type E2. This possible 
acetylation presents a novel regulatory step in the PV replication program, and 
could be directly involved in the transition from maintenance stage replication to 
vegetative amplification. 
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Figure 4.1 
 
 
Figure 4.1 A proposed mechanism for the regulation of replication by 
acetylation of E2 K111. HPV31 E2 regulates replication initiation through K111 
acetylation dependent Topo1 recruitment.  This illustration depicts the dynamics 
between E1, E2, RPA, and Topo1 at the replication fork, and the role of K111 
acetylation.  
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APPENDIX 
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Table A-1 
HPV31 HA-E2 Cloning Primers 
	 	
Primer Name 
(mutation) 
Primer Sequence 
HPV31-K111R F CCTACAGGGTGTTTAAGAAAACATGGATATACTG 
HPV31-K111R R CAGTATATCCATGTTTTCTTAAACACCCTGTAGG 
HPV31-K112R F CCTACAGGGTGTTTAAAAAGACATGGATATACTG 
HPV31-K112R R CAGTATATCCATGTCTTTTTAAACACCCTGTAGG 
HPV31-K111R112R F CCTACAGGGTGTTTAAGAAGACATGGATATACTG 
HPV31-K111R112R R CAGTATATCCATGTCTTCTTAAACACCCTGTAGG 
HPV31-K111Q F CCTACAGGGTGTTTACAAAAACATGGATATACTG 
HPV31-K111Q R CAGTATATCCATGTTTTTGTAAACACCCTGTAGG 
HPV31-K112Q F CCTACAGGGTGTTTAAAACAACATGGATATACTG 
HPV31-K112Q R CAGTATATCCATGTTGTTTTAAACACCCTGTAGG 
HPV31-K111Q112Q F CCTACAGGGTGTTTACAACAACATGGATATACTG 
HPV31-K111Q112Q R CAGTATATCCATGTTGTTGTAAACACCCTGTAGG 
HPV31-K111Q112R F CCTACAGGGTGTTTACAAAGACATGGATATACTG   
HPV31-K111Q112R R CAGTATATCCATGTCTTTGTAAACACCCTGTAGG 
HPV31-K111Q112A F CCTACAGGGTGTTTCAAGCAACATGGATATACTG 
HPV31-K111Q112A R CAGTATATCCATGTTGCTTGAAACACCCTGTAGG 
HPV31-K111A F CCTACAGGGTGTTTAGCAAAACATGGATATACTG   
HPV31-K111A R CAGTATATCCATGTTTTGCTAAACACCCTGTAGG 
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Table A-2 
 
HPV31 Codon-optimized flag-E2 Cloning Primers 
 
Primer	Name	(mutation)	 Primer	Sequence	
HPV31-K111R F ACCGGCTGCCTGAGGAAGCACGGCTAC 
HPV31-K111R R GTAGCCGTGCTTCCTCAGGCAGCCGGT 
HPV31-K112R F CACCGGCTGCCTGAAGAGGCACGGCTA 
HPV31-K112R R TAGCCGTGCCTCTTCAGGCAGCCGGTG 
HPV31-K111R112R F TCCCACCGGCTGCCTGAGGAGGCACGGCTA 
HPV31-K111R112R R TAGCCGTGCCTCCTCAGGCAGCCGGTGGGA 
HPV31-K111Q F CACCGGCTGCCTGCAGAAGCACGGCTA 
HPV31-K111Q R TAGCCGTGCTTCTGCAGGCAGCCGGTG 
HPV31-K112Q F CGGCTGCCTGAAGCAGCACGGCTACAC 
HPV31-K112Q R GTGTAGCCGTGCTGCTTCAGGCAGCCG 
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Table A-3 
 
HPV31 Sequencing Primers  
 
Primer Name 
(mutation) Primer Sequence 
HPV31-E2 Seq F GGAAGGGCAAGTTAATTGTAAGGGC 
HPV31-E2 Seq R CCTGACCACCCGCATGCACTTC 
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Table A-4 
Bacterial (Glycerol) Stocks 
 
Plasmid Resistance Vector Cell Notes 
pCG-BPV E2 AMP pCG DH5α   
pCG-BPV E2 K70R AMP pCG DH5α   
pCG-BPV E2 K107R AMP pCG DH5α   
pCG-BPV E2 K111R AMP pCG DH5α   
pCG-BPV E2 K112R AMP pCG DH5α   
pCG-BPV E2K111R112R AMP pCG DH5α   
pCG-BPV E2K339R AMP pCG DH5α   
pCG-BPV E2 K391R AMP pCG DH5α   
pCG-BPV E2 W145R AMP pCG DH5α   
          
pCG-BPV E1 AMP pCG DH5α   
pGL2-E2BS-LUC AMP pGL2 DH5α   
          
HPV31 HA-E2 AMP pCI DH5α   
HPV31 HA-E2 K111R AMP pCI DH5α   
HPV31 HA-E2 K111A AMP pCI DH5α   
HPV31 HA-E2 K111Q AMP pCI DH5α   
HPV31 HA-E2 K112R AMP pCI DH5α   
HPV31 HA-E2 K112Q AMP pCI DH5α   
HPV31 HA-E2 
K111R112R AMP pCI DH5α   
HPV31 HA-E2 
K111R112Q AMP pCI DH5α   
HPV31 HA-E2 AMP pCI GM119 Dam-/Dcm- 
HPV31 HA-E2 K111R AMP pCI GM119 Dam-/Dcm- 
HPV31 HA-E2 K111A AMP pCI GM119 Dam-/Dcm- 
HPV31 HA-E2 K111Q AMP pCI GM119 Dam-/Dcm- 
HPV31 HA-E2 K112R AMP pCI GM119 Dam-/Dcm- 
HPV31 HA-E2 K112Q AMP pCI GM119 Dam-/Dcm- 
HPV31 HA-E2 
K111R112R AMP pCI GM119 Dam-/Dcm- 
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Plasmid Resistance Vector Cell Notes 
HPV31 Flag-E2 AMP pCI DH5α 
Codon 
optimized 
HPV31 Flag-E2 K111R AMP pCI DH5α 
Codon 
optimized 
HPV31 Flag-E2 K111A AMP pCI DH5α 
Codon 
optimized 
HPV31 Flag-E2 K111Q AMP pCI DH5α 
Codon 
optimized 
HPV31 Flag-E2 K112R AMP pCI DH5α 
Codon 
optimized 
HPV31 Flag-E2 K112Q AMP pCI DH5α 
Codon 
optimized 
HPV31 Flag-E2 
K111R112R AMP pCI DH5α 
Codon 
optimized 
          
HPV31 3x-Flag-E1 KAN   DH5α 
Codon 
optimized 
          
Flag-Brd4 AMP pcDNA3 DH5α   
hBRD4: BID AMP pGEX DH5α   
hBRD4: PDID AMP pGEX DH5α   
hBRD4: CTM AMP pGEX DH5α   
          
HPV31 Genome AMP pBR322 DH5α   
          
pCI-Rluc AMP pCI DH5α   
pFLORI31 AMP pCI DH5α   
pFLORI-BPV AMP pCI DH5α   
      DH5α   
HA-AMF1 AMP pCDNA DH5α   
          
pUC18 AMP   DH5α   
pUC19 AMP   DH5α   
pCI AMP   DH5α   
pBabe-puro AMP   DH5α   
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Table A-5 
 
Cell Lines  
 
Cell Line Media Notes 
C33A DMEM 		
293TT DMEM 		
J23T3 DMEM 		
H1299 DMEM 		
CV-1 DMEM 		
		 		 		
NIKS F-MEDIA on feeders 
CIN612 E-MEDIA on feeders 
HPVFP KSFM 		
		 		 		
HK1 KSFM primary HFK 
HK2 KSFM primary HFK 
HK3 KSFM primary HFK 
HK4 KSFM primary HFK 
		 		 		
NIKS31  wt F-MEDIA on feeders 
NIKS31 K111R F-MEDIA on feeders 
NIKS31 K111Q F-MEDIA on feeders 
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